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This dissertation includes three studies, all focusing on utilizing Big Data and statistical 
methods for improving one of the most important aspects of health care, namely drug 
safety. In these studies we develop data analytics methodologies to inspect, clean, and 
model data with the aim of fulfilling the three main goals of drug safety; detection, 
understanding, and prediction of adverse drug effects. 
In the first study, we develop a methodology by combining both analytics and statistical 
methods with the aim of detecting associations between drugs and adverse events through 
historical patients’ records. Particularly we show applicability of the developed 
methodology by focusing on investigating potential confounding role of common 
diabetes drugs on developing acute renal failure in diabetic patients. While traditional 
methods of signal detection mostly consider one drug and one adverse event at a time for 
investigation, our proposed methodology takes into account the effect of drug-drug 
interactions by identifying groups of drugs frequently prescribed together. 
In the second study, two independent methodologies are developed to investigate the role 
of prescription sequence factor on the likelihood of developing adverse events. In fact, 
this study focuses on using data analytics for understanding drug-event associations. Our 
analyses on the historical medication records of a group of diabetic patients using the 
proposed approaches revealed that the sequence in which the drugs are prescribed, and 
administered, significantly do matter in the development of adverse events associated 
with those drugs. 
The third study uses a chronological approach to develop a network of approved drugs 
and their known adverse events. It then utilizes a set of network metrics, both similarity- 
and centrality-based, to build and train machine learning predictive models and predict 
the likely adverse events for the newly discovered drugs before their approval and 
introduction to the market. For this purpose, data of known drug-event associations from 
a large biomedical publication database (i.e., PubMed) is employed to construct the 
network. The results indicate significant improvements in terms of accuracy of prediction 
of drug-evet associations compared with similar approaches.
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Today every drug goes through a long journey which ,on average, takes 10-15 years (Iizuka, 2007) 
from the first day it is discovered until its approval by healthcare authorities and introduction to the 
market. This involves numerous clinical trials aiming at ensuring efficacy and safety of the drug. 
In other words, the clinical trials are meant to ensure that, first, a given drug efficiently functions 
as it is intended to treat disease(s), and second, it does not cause any serious side effects to the 
patients. 
Pharmacovigilance, also referred to as drug safety surveillance, has been defined as the science and 
activities relating to the detection, assessment, understanding, prediction, and prevention of adverse 
effects or any drug problem (Arthur et al., 2002). In the pharmacovigilance terminology, Adverse 
Drug Events (ADE) is a general term that refers to any injury caused by a medication. This injury 
can be an unintended effect of the recommended (i.e. prescribed or labeled) usage of a drug, the 
off-label usage of a drug, or a medication error (Karimi, Wang, Metke-Jimenez, Gaire, & Paris, 
2015). Adverse Drug Reactions (ADR), on the other hand, is a more specific term that only refers 




Pharmacovigilance activities are deemed to be important from both health and business perspectives. 
It is reported that ADEs in each year cause more than 2 million injuries, hospitalizations, and deaths 
only in the United States (Lazarou, Pomeranz, & Corey, 1998) that incur more than 75 billion dollars 
to the patients, healthcare system, and insurance agencies (Ahmad, 2003). 
1.1. PRE-APPROVAL PHARMACOVIGILANCE 
Although pharmacovigilance activities for any drug begin a long time before introducing it to the 
market through numerous pre-approval clinical trials, such efforts are typically too limited to identify 
all the potential ADEs that may occur. First, they are often short in time and involve a limited sample 
size (Zeng, Kogan, Ash, Greenes, & Boxwala, 2002). Moreover, they do not fully represent the target 
population of the drug as they may exclude patients who receive other medications, focus on a particular 
age group (e.g. elderly) of patients, and those who have complicated medical conditions (Karimi et al., 
2015). Also as Stephens and Talbot (1985) noted, clinical trials may not detect ADEs with very low 
incident rates.  
1.2. POST-APPROVAL PHARMACOVIGILANCE 
Due to the mentioned points in the previous section, post-approval ADEs have always been a major 
global health concern since a considerable proportion of ADEs remain to be revealed in the post-
approval stage of the drugs’ lifetime. In some cases, those unrevealed ADEs in the pre-approval stage 
have even caused thousands of deaths; A classic example of such cases is Rofecoxib; an NSAID 
approved in 1999 that became highly welcomed by the physicians in a short time. The drug was 
originally aimed to treat acute pains and Osteoarthritis, but after a while turned out to cause heart attacks 
in more than 100,000 patients and ended up being withdrawn by the FDA in 2004. 
Unlike pre-approval stage which is highly experiment-based, post-approval pharmacovigilance is 
highly driven by historical data analysis. Given the critical importance of post-approval 
pharmacovigilance from both healthcare and business perspectives, and in response to the challenge 
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posed by large quantities and complexities of data sources that needed to be examined, various data 
mining algorithms have been developed in the recent decades to bring about improvement in drug safety 
surveillance. Researchers have used various approaches, all with a heavy reliance on information 
systems for collection, manipulation, and analysis of data. Four main types of data source have been 
identified in the literature to be used in ADE studies. The following four sub-sections introduce these 
resources and mention prior research conducted using each. 
1.2.1. SPONTANEOUS REPORTING SYSTEMS 
As an effort to rapidly detect and prevent ADEs, many countries and international organizations have 
run Spontaneous Reporting Systems (SRSs), systems designed to allow patients and professionals to 
submit their reports of suspected ADEs. This includes the World Health Organization’s (WHO) 
Individual Case Safety Reports (ICSR) database, the TGA Adverse Drug Reaction System (ADRS) in 
Australia, the yellow card system of Medicines and Healthcare products Regulatory Agency (MHRA) 
in the UK, and the FDA Adverse Event Reporting System (FAERS) in the US (Karimi et al., 2015). 
Although SRSs have been the main source to detect likely ADE cases for years and multiple studies 
were conducted based on them,(Cai et al., 2017; DuMouchel, 1999; Lin, Xiao, Huang, Chiu, & Soo, 
2010; van Puijenbroek et al., 2002) they still have several limitations such as over-reporting, missing 
and incomplete data, latency, duplicated reporting and voluntary submission (Harpaz et al., 2013). Due 
to voluntary submission, for instance, it is estimated that these systems in the US and UK reflect less 
than 10% of the ADE occurrences.(Inman & Pearce, 1993; Yang, Jiang, Yang, & Tang, 2012) Such 
shortcomings made pharmacovigilance practitioners shift their focus towards resources that are more 
efficient for post-marketing drug surveillance. 
1.2.2. ELECTRONIC HEALTH RECORDS (EHR) 
In the past decade and along with extensive adoption of information systems and technologies in the 
healthcare industry, Electronic Health Records (EHR) have been widely used in this industry to help 
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practitioners in the collection, storage, and tracking patients' information. The vast amount of data 
collected by EHRs along with their increasing availability have made them interesting resources for 
pharmacovigilance researchers and enabled them to detect ADE signals1 closer to real-time (Trifirò et 
al., 2009). Although EHR data is generally more complete than SRSs reports and several studies have 
been conducted recently using EHRs (Friedman, 2009; Haerian et al., 2012; Harpaz et al., 2012; 
Harpaz, Haerian, Chase, & Friedman, 2010), yet using them for ADE studies involve challenges like 
complex data preprocessing requirements and various data documentation styles across different 
providers (Harpaz et al., 2013). 
1.2.3. SOCIAL MEDIA 
In the recent years, social media has also been considered as a key data source for collecting drugs’ 
post-marketing feedbacks by multiple researchers (Hoang et al., 2016; J. Liu, Zhao, & Zhang, 2016; X. 
Liu & Chen, 2013; Nikfarjam, Sarker, O’Connor, Ginn, & Gonzalez, 2015a; O’Connor et al., 2014). A 
Pew internet research by Fox and Jones(2009) found that 61% of Americans look for health information 
online. This is normally done either through healthcare online forums such as ‘DailyStrength’ and 
‘PatientsLikeMe’; or through social networks like Facebook and Twitter. Through the social media, 
people talk about their concerns, seek advice about their health issues, and discuss their medical 
experiences. Such information, although noisy, is likely to appear there long before it is reported to any 
SRS or recorded in any EHR (Benton et al., 2011; Leaman et al., 2010). A novel stream of research 
using Twitter data focuses on automatic detection of ADEs by constant monitoring of tweets posted by 
patients using text-mining approaches. Sarker et al. (2015) have done a comprehensive review of the 
studies conducted in this area.  
                                                     
1 Signal is defined by the World Health Organization (WHO) as information on a possible causal relationship 




1.2.4. BIOMEDICAL LITERATURE 
Recently, researchers have realized biomedical literature as well as chemical and biological databases 
as feature-rich sources for pharmacovigilance studies. Databases such as PubMed, PubChem, KEGG, 
and DrugBank are rich sources of information about drugs, their chemical and biological 
characteristics, and their identified ADEs. Several studies have been done by employing data- and text-
mining techniques on data from these resources(Avillach et al., 2013; Shetty & Dalal, 2011) or even 
by combining them with other mentioned resources(Duke et al., 2012) to detect or predict ADEs. 
1.3. CLASSIFICATION OF PHARMACOVIGILANCE STUDIES 
The type of data source we use for a study determines the class of data mining algorithms that can be 
applied. The following sections discuss various types of data mining approaches used in the 
pharmacovigilance literature. 
1.3.1. METHODS FOR ASSOCIATION DETECTION AND UNDERSTANDING 
The main class of data mining approaches widely used in pharmacovigilance research are those 
designed to detect meaningful association (i.e. signal) for large sets of drug-event pairs with the aim of 
identifying and prioritizing risk signals. Of course, the identified signals should then be investigated 
more carefully to verify the causality between drug and event. This approach is especially applied 
widely to the SRS data. For example FDA actively uses a data mining engine to compute signal scores 
indicating statistical associations for millions of drug-event combinations in the AERS (Harpaz et al., 
2013). Such DM algorithms are in fact an extension of the Disproportionality Analysis (DPA) methods 
that, for years, were the main statistical methods to discover drug-event associations based on frequency 
analysis of 2x2 contingency tables (Bate & Evans, 2009). Given that EHR data, as opposed to SRS, 
involves information on both ADE and non-ADE cases as well as temporal patients information, 
modified versions of DPA are typically used to analyzed their data. For instance Schuemie (2011) 
proposed a DPA-based longitudinal approach to detect ADE signals in the EHR data to take into 
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account the effect of “length of exposure to a drug” on potential adverse events. However, unlike DPA 
methods which are only able to detect associations involving one drug and one event, DM-based 
approaches are capable to handle more complex situations such as drug-drug interactions, drug-induced 
syndromes, and confounding phenomena (Harpaz et al., 2013). 
Apart from DPA extensions, the literature also involves studies that employed methods based on 
logistic regression and unsupervised machine-learning methods for the same purposes.  
Logistic regression-based approaches are especially handy when the goal is to handle multiple potential 
confounding factors2. While the traditional approach to control for confounders is stratification, that 
approach is not very effective in presence of too many confounders. Jewel (2003) argues that in such 
cases a more appropriate approach to handle confounding is to incorporate all potential confounders as 
covariates in a logistic regression model. Nevertheless, even the original logistic regression approach 
is limited in terms of the number of covariates that can handle. Some newer extensions of logistic 
regression, namely Bayesian Logistic Regression (BLR) models are even capable to handle millions of 
covariates in the model. Such models have been used in a number of studies such as (Caster, Norén, 
Madigan, & Bate, 2010) to detect ADE signals from the WHO spontaneous reporting system data 
controlling for too many confounding factors. 
Unsupervised machine-learning approaches are another class of DM algorithms that are used for signal 
detection. Many studies have used association rule mining to discover multi-item ADE associations 
(Harpaz, Chase, & Friedman, 2010; Ji et al., 2011; Reps, Aickelin, & Hubbard, 2016). Nevertheless, 
these methods typically require substantial computing resources which has limited their application in 
the past. Clustering methods have also been used in a number of pharmacovigilance studies, primarily 
as an exploratory tool with the aim of summarizing the complex structures in a macroscopic manner. 
                                                     
2 A confounder by definition is an extraneous variable that mediates an association between two other variables 
(i.e. drug and event). (Harpaz et al., 2013) 
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For example, He et al (2004) applied a KNN clustering algorithm to the drug dispensation sequence 
data from patients with the disease Angioedema to discover potential relationships between drugs and 
resulting hospital admissions due to adverse events. 
Network analysis is another approach that researchers have recently started to use, mostly to discover 
interesting multidimensional patterns of ADEs. Applying a network approach to the FDA’s 
spontaneous reporting database, for instance, Ball et al (2011a) revealed that the vaccine HPV4 is 
associated with syncope and seizures in adolescents.  
Given the fact that EHR data contains information about both ADE and non-ADE groups of patients, a 
popular class of approaches applied to such data are those based on comparison of patterns and 
frequencies across these groups. That involves studies which employ cohort designs, case-control 
designs, or self-controlled designs to compare the two groups. In the cohort design studies, the idea is 
that the patterns of ADE occurrence over time must be different among patients who were exposed to 
a suspicious drug and those who were not; if so, it is likely to say that there is an association between 
the drug and the event of interest. On the case-control designs, on the other hand, comparison is made 
between patients who experienced a particular adverse event and those who did not. Different patterns 
of drug taking between them, then implies likely association. In the self-controlled design, each patient 
who has experienced the ADE, is treated as both the case and control subject in the study (i.e. during 
the drug exposure vs non-exposure periods) and the patterns of ADE across the two periods are 
compared against each other. 
Apart from the medication information, electronic medical records also contain a variety of other 
structured and unstructured data that have been used in the pharmacovigilance research to detect ADE 
signals. Park et al (2011) for instance used lab reports in an EHR database to identify abnormal lab 
results and compare their patterns before and after the use of a medication.  
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1.3.2. METHODS FOR PREDICTING ASSOCIATIONS 
Even though most of the research conducted based on SRS and EHR data are focused on detecting 
signals of associations between drugs and adverse events (either directly or due to interactions) as well 
as understanding the factors moderating them, recently emergence of some new data sources (such as 
chemical and biological information of drugs, biomedical literature, patients’ online forums, and social 
networks) has led to efforts to predict ADEs at the early stages of drug’s lifecycle and before it affects 
too many people.  
Quantitative Structure-Activity Relationship (QSAR) is a regression-based method widely used in the 
chemical and biological sciences that primarily aims at predicting biological activity of chemicals (i.e. 
the response) based on their chemical and molecular structure. Relying on QSAR, and using historical 
causal drug-event associations, some research is conducted to identify chemical properties of molecules 
that may correlate with ADEs and thereby to predict potential ADEs of new drugs on the basis of their 
chemical properties (Matthews et al., 2009; Pouliot, Chiang, & Butte, 2011). Such QSAR models are 
now being used internally by the FDA to provide decision support information for a variety of purposes 
(Harpaz et al., 2013). 
In another group of studies, text-mining techniques have been applied to the unstructured data collected 
from biomedical literature (e.g. Shetty & Dalal, 2011) as well as patients’ online communities and 
social networks (e.g. Leaman et al., 2010) with the aim of identifying drugs’ potential adverse events 
earlier than they are reported to the spontaneous reporting systems. Some prominent ADE cases such 
as the Rofecoxib case have been used in these studies as benchmark to show how the prediction methods 
were able to predict that case much earlier than it causes more than 100,000 myocardial infarctions and 
collected from market due to numerous reports filed for it to the FDA’s SAERS in 2004. 
Another approach used in the literature to predict ADEs is network analysis. Cami et al (2011) used 
historical drug-event associations to construct a network having both drugs and events as nodes and 
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their associations represented by edges. They used topological network measures along with drugs’ 
molecular descriptors to train a logistic regression model to predict the likelihood of existence of an 
edge (i.e. association) for each drug-event pair.   
Combining canonical correlation analysis and network-based diffusion, Atias and Sharan (2011) 
proposed a novel prediction approach and applied that to a public database of drug side effects called 
SIDER, to predict ADEs of the new drugs. They validated their model by testing it on a set of 692 drugs 
with known side effects and showed that for 34% of the drugs the top scoring side effect identified by 
the algorithm matches a known side effect of the drug. 
1.4. AN OVERVIEW OF THE CURRENT WORK 
The present dissertation work involves three independent studies. To highlight the role of various 
information systems as well as data analysis methods in pharmacovigilance, in these studies multiple 
data sources, each relied on an IS artifact, have been utilized and a handful of data mining and statistical 
methods has been used to analyze that data with the aim of improving drug safety. 
 In terms of approach and data source, the first study aims at detecting ADE signals by applying data 
mining and statistical methods to EHR transactional data. Specifically, the goal of the first study is to 
investigate potential adverse reactions of common diabetic drugs in developing acute renal failure. 
The second study employs data mining and statistical techniques along with EHR data with the aim of 
understanding drug-ADE associations. The goal in that study is to investigate the role of prescription 
sequence factor in changing the likelihood of development of adverse events for the already known 
drug-ADE associations. As a case study, we have focused on acute renal failure as a common and high-
risk adverse event to address the research question of the second study. 
The third essay deals with another aspect of pharmacovigilance studies, namely ADE prediction. In that 
study a chronological network approach along with multiple machine learning techniques have been 
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employed with the aim of identifying similarities among the already-approved drugs and the new drugs 
and  then using those similarities to predict potential ADEs of new drugs before their approval. To this 
end, we have used reported drug-ADE associations mentioned in the biomedical literature (MEDLINE 
database) as the main data source and have enriched that with data on the target proteins of drugs in the 
human body (i.e. a biological property of the drugs). 
Overall, in the three studies conducted, we have tried to highlight the potential of using IS artifacts (i.e. 
databases and computer-based data analysis techniques) to contribute to various aspects of drug safety 
(i.e. detection, understanding, and prediction of signals). 









ESSAY I: THE CONFOUNDING ROLE OF COMMON DIABETES MEDICATIONS 
IN DEVELOPING ACUTE RENAL FAILURE: A DATA MINING APPROACH WITH 
EMPHASIS ON DRUG-DRUG INTERACTIONS 
 
ABSTRACT 
Longstanding diabetes mellitus is today known as the primary reason for kidney failure in the 
patients having that condition. While the prior research has studied the confounding role of some 
frequently prescribed diabetes medications in developing acute renal failure, some rarely 
prescribed medications are still under-studied in this regard. In addition, even for those drugs 
studied in the past, inconsistent findings have been reported. In the present study, by extending a 
data mining framework from the prior research and equipping that with some standard statistical 
metric from the medical literature we investigate the general confounding role of the common 
diabetes medications in developing acute renal failure in a large group of patients with diabetes 
mellitus (Type II). In addition, we assess the stability of the identified confounding roles by 
taking into account the potential drug-drug interactions between those diabetes medications with 
a group of drugs already known to have negative effect on the kidney function. Our results 
suggest the general dominant confounding role for each of the diabetes medications, but also 
suggests that these roles are unstable across various prescription combinations due to potential 
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drug-drug interactions, thereby provide an explanation for the inconsistent findings in the 
literature. 



















2.1. INTRODUCTION  
Today almost every drug produced and marketed by pharmaceutical companies has a list of likely 
side effects printed on its label to warn patients about possible harms they may undergo by taking 
it. Such known side effects are usually the result of several years of research and clinical trials 
conducted on the drug by the manufacturer after discovery and before introducing it to the 
market. 
In the pharmacovigilance3 terminology, Adverse Drug Event (ADE) is a general term that 
refers to any injury caused by a medication. This injury can be an unintended effect of the 
recommended (i.e. prescribed or labeled) usage of a drug, the off-label usage of a drug, or a 
medication error (Karimi et al., 2015). Adverse Drug Reactions (ADR) are a subset of ADEs 
referring to an unexpected harm caused by the normal use of medication at the normal dosage 
(Karimi et al., 2015). Therefore, ADRs does not have to do with non-prescribed or off-label usage 
of a drug or medication errors. In the United States, according to the Office of Disease Prevention 
and Health Promotion (ODPHP), ADRs account for about 2 million hospital stays as well as 3.5 
million physician office visits in each year4. Also, the cost incurred by each ADR case in 
community hospitals in the United States is estimated at around $3,000 (Classen, Pestotnik, 
Evans, Lloyd, & Burke, 1997; Hug, Keohane, Seger, Yoon, & Bates, 2012).  
Such considerable costs to the patients, insurance agencies, and the healthcare industry 
have caused researchers to seek effective ways for detection, prediction, and prevention of ADRs 
during the past years. The development of Electronic Health Records (EHR) systems in the past 
decade has provided pharmacovigilance researchers with great opportunities to detect, predict, 
and understand adverse drug reactions by analyzing real medical transactions. 
                                                     
3 Pharmacovigilance (a.k.a. drug safety surveillance) is a field of science that tries to detect, assess, 
understand, and prevent harms and injuries caused by medications in all stages of drugs’ lifetime (i.e. 
discovery, clinical trials, pre-marketing, and post-marketing). (World Health Organization) 
4 https://health.gov/hcq/ade.asp  
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Acute Renal Failure is one of the most common ADRs due to taking medications 
identified in the literature (Trifirò et al., 2009). The literature has mentioned several drugs with 
renal failure as one of their main side effects (Ashley, 2018; Cavalieri et al., 2018; Härmark, Van 
Der Wiel, De Groot, & Van Grootheest, 2007; Perazella, 2003; Singh, Ganguli, & Prakash, 
2003). Also, diabetes mellitus is known as the leading cause of chronic and end-stage kidney 
disease as Loh and Cohen (2009) and Afkarian and colleagues (2016) note that diabetes mellitus 
accounts for most of the cases of kidney disease in the United States and other developed 
countries. Whereas common diabetes medications are not known as major causes of renal failure 
in the literature, there are studies which suggest some confounding roles for these medications in 
increasing or decreasing the chances of renal failure development. However, those analyses are 
mostly focused on frequently prescribed diabetes medications (e.g., insulin and metformin); 
moreover, in some cases, inconsistent confounding roles have been suggested for the same drug 
by different researchers.  
Although various data-driven methods such as disproportionality analysis (Baksh, 
McAdams‐DeMarco, Segal, & Alexander, 2018; Cohen, Houdeau, & Khromava, 2018; Trippe, 
Brendani, Meier, & Lewis, 2017), text analysis (Harpaz et al., 2013; Nikfarjam et al., 2015a), and 
network analysis (Cami et al., 2011; Davazdahemami & Delen, 2018) are proposed in the 
literature to identify drug’s potential adverse events, little research has been done on the potential 
confounding role of drugs in development of adverse events in the presence of other drugs. In 
fact, the drug-ADR associations are mostly studied in isolation, whereas prior research suggests 
that unintended drug-drug interactions (DDIs) may help developing an adverse event in these 
patients.  
Almost all the DDI studies in the literature involve investigation of potential reactions 
between pairs of drugs whereas many interactions might be the result of taking three or more 
drugs in a time period. In the present study, we extend the framework proposed by Reps et al. 
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(2016) and apply it to the prescription records of a large set of diabetic patients to: 1) investigate 
the general confounding role of common diabetes medications, including those infrequently 
prescribed drugs, controlling for the effect of kidney-damaging drugs; and 2) assess the stability 
of those confounding roles across various prescription combinations of the same drug (i.e., 
assessing the potential DDIs) with the aim of explaining inconsistent confounding roles reported 
in the prior studies. 
The remainder of the paper is organized as follows. In section 2 through a review of the 
literature, we discuss the pre- and post-approval ADR research as well as various approaches 
employed in prior research for this purpose. Finally, we explain the research goals in the last part 
of that section. Following that, in section 3 we elaborate the proposed approach as well as the 
settings of the case study conducted to showcase that. Next, the results are presented (section 4) 
followed by a discussion of theoretical and empirical implications in section 5.  
2.2. LITERATURE REVIEW 
2.2.1. PRE- AND POST-APPROVAL ADR RESEARCH 
It takes ten to fifteen years, on average, for a new drug to pass through the required clinical trials, 
get approved, and be introduced to the market (Iizuka, 2007). However, even after this long 
process, it is unlikely that all the risks associated with taking a drug have been identified. It is 
particularly due to limitations involved in lab experiments. They are often conducted over short 
timeframes and involve only a limited sample size. In addition, they are focused only on a 
particular group and usually exclude patients with complicated medical conditions (Karimi et al., 
2015; Zeng et al., 2002). Moreover, these trials may not detect drug reactions with very low 
incidence rates (Stephens & Talbot, 1985). Due to these shortcomings, the side effects of a 
considerable number of drugs are often only revealed in the post-approval stage.  
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As a post-approval effort to rapidly detect and take appropriate action to ADRs, many countries 
and healthcare organizations have run Spontaneous Adverse Drug Reporting Systems (SAERSs); 
information systems designed to allow patients and professionals to submit their reports of 
suspected adverse drug events. Some of the examples of such systems are the yellow card system 
of Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom, and 
the FDA Adverse Event Reporting System (FAERS) in the United States (Karimi et al., 2015).  
Although spontaneous reporting systems have been the main source to detect likely ADR cases 
for years, they still have several limitations such as over-reporting of highly common ADRs, 
missing and incomplete data, duplicated reporting and voluntary submission (Harpaz et al., 2013). 
Due to the voluntary submission of the reports, for instance, it is estimated that these systems in 
the US and UK reflect less than 10% of the adverse effect occurrences (Inman & Pearce, 1993; 
Yang et al., 2012). Such shortcomings led pharmacovigilance practitioners to look for resources 
that are more efficient for post-approval drug surveillance. 
In recent years, Electronic Health Records (EHR) have been widely used in the healthcare 
industry to help practitioners in collection, storage, and tracking patients' information and their 
treatment progress. The vast amount of data collected by EHRs as well as their increasing 
availability of low-cost EHR platforms to the healthcare providers have made them interesting 
resources for pharmacovigilance researchers and presented opportunities to investigate and detect 
ADR signals5 closer to real-time (Trifirò et al., 2009). Several data mining approaches have been 
proposed and applied by data scientists to EHR data in the past few years (Bao, Kuang, Peissig, 
Page, & Willett, 2017; Friedman, 2009; Polimeni et al., 2009; Santiso, Casillas, & Pérez, 2018; 
Trifirò et al., 2009). Despite utilizing EHR data for pharmacovigilance purposes have gained 
                                                     
5 In pharmacovigilance, a signal is defined by the WHO as information on a possible causal relationship 
between an adverse event and a drug, which is unknown or incompletely documented (Trifirò et al., 2009). 
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much interest from European and Australian researchers, there is still a lack of sufficient research 
by the US academics and practitioners on the EHR data from the US healthcare market. Even 
though EHR data is generally more complete than data collected by spontaneous reporting 
systems, yet using this data for detection and prediction of ADR cases involves challenges such 
as complex data preprocessing requirements and various data documentation styles across 
different healthcare organizations (Harpaz et al., 2013).  
Social media has also been considered as a key data source for monitoring drugs’ post-marketing 
feedbacks in the recent few years. This is normally done either through healthcare online forums 
such as ‘Ask a patient’, ‘Dailystrength’, and ‘PatientsLikeMe’ (Karimi, Kim, & Cavedon, 2011; 
Leaman et al., 2010; X. Liu & Chen, 2013); or through social networks like Facebook and Twitter 
and by applying text-mining and sentiment analysis methods (Ginn et al., 2014; Nguyen et al., 
2017; Prier, Smith, Giraud-Carrier, & Hanson, 2011). 
2.2.2. TAXONOMY OF ADR STUDIES 
In terms of research goals, pharmacovigilance studies can be classified into three categories, 
namely detection, prediction, and understanding studies (Davazdahemami & Delen, 2018).  
Detection studies mainly aim at identifying existing associations (not necessarily causal) 
between drugs and potential adverse reactions, often by analyzing historical usage data obtained 
from various resources. Of course, additional clinical trials are needed to assess and verify the 
causality of associations detected by this type of ADR studies, however, it is still valuable to 
identify potential ADR that might be caused by a medication and focus the expensive and time 
consuming clinical trial activities on them.  
Prediction studies are those that utilize information about already known drug-ADR 
associations to predict possible ADRs for the newly discovered as well as existing drugs. While 
detecting and predicting potential associations is a critical task, it is clear that such associations 
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do not hold all the time and in case of every patient. That is why, for instance, that a particular 
patient might experience a side effect of a given drug, while that drug may not have any adverse 
effect in another patient. Hence, it is crucial to investigate and understand the mechanism through 
which drugs develop side effects in the patients by identifying factors that either intensify or 
mitigate the strength of a drug-ADR association. This is, in fact, the goal of the understanding 
group of pharmacovigilance studies. 
Many studies have been done in the past with the aim of detecting ADR signals for 
various drugs. In terms of methodology, some of them (Cai et al., 2017; van Puijenbroek et al., 
2002) have used traditional statistical methods for this purpose, whereas many other studies 
(Friedman, 2009; Harpaz et al., 2013; Harpaz, Haerian, et al., 2010; X. Liu & Chen, 2013; 
Nikfarjam et al., 2015a; Reps et al., 2016; Trifirò et al., 2009) have employed data mining and 
analytics techniques to detect ADR signals. Association rule mining techniques have been shown 
in prior research to be highly efficient in extracting patterns from healthcare data (Borah & Nath, 
2018; Harpaz, Chase, et al., 2010; Kuo, Lin, & Shih, 2007; W. H. Lee, Wang, & Chen, 2017; 
Nahar, Imam, Tickle, & Chen, 2013; Piri, Delen, Liu, & Paiva, 2018). Also in terms of data, 
various resources have been used in the past ADR detection studies including SAERSs (Cai et al., 
2017; DuMouchel, 1999; Harpaz et al., 2013; van Puijenbroek et al., 2002), EHRs (Casillas, 
Pérez, Oronoz, Gojenola, & Santiso, 2016; Friedman, 2009; Haerian et al., 2012; Harpaz, 
Haerian, et al., 2010; Reps et al., 2016; Trifirò et al., 2009), and social media (Hoang et al., 2016; 
J. Liu et al., 2016; X. Liu & Chen, 2013; Nikfarjam et al., 2015a). 
While most of the prior ADR detection studies are focused on identifying associations 
between drug-ADR pairs, many ADRs are actually the outcome of drug-drug interactions (DDIs) 
among two or more drugs that are prescribed and administered together in a short time window. 
Compared to the regular ADR detection studies, little research has been done on identifying such 
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DDIs, especially for studying DDIs involving more than two drugs and their potential role in 
developing ADRs. 
2.2.3. RESEARCH GOALS 
Reps et al.(2016) proposed a framework for refining ADR signals including sets of drugs 
obtained via longitudinal observational (EHR) data. In the present study, we extend their 
framework by adding extra assumptions and combining it with some standardized statistical 
metrics and apply that to the prescription records of a group of diabetic patients with the aim of 
identifying the general confounding roles of common diabetes medications in developing renal 
failure. In addition, we assess the stability of their roles across various prescription combinations 
to highlight their potential interactions with other relevant drugs, which leads them to act in an 
unexpected way with respect to developing renal failure.  
The proposed framework in the current study differs from that of Reps et al. in two 
specific aspects; first, unlike their approach which relies on the “lift” measure to identify frequent 
itemsets that are more frequent among case patients than among control patients, we use a 
statistical metric for comparing case and control patients and rely on statistical significance of 
difference for judging about the confounding effect. Second, in our proposed approach the focus 
is on identifying the confounding role of single drugs by taking into account their potential 
interaction with other drugs, as opposed to Reps et al. that mainly investigate the confounding 
effect of the whole itemset.  
In fact, our study is an event-based type of data mining analysis as defined by Trifirò et 
al.(2009), in which the focus is on one or a set of specific events (i.e., renal failure) for their 
association with possible drugs that may cause them. There is an event-based stream of research 
focused on investigating the drugs associated with kidney diseases in general and acute renal 
failure in particular (Cavalieri et al., 2018; Coca & Perazella, 2002; Heerspink et al., 2017; J. 
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Huang, 2018; Izzedine, Launay-Vacher, & Deray, 2005; Kimura et al., 2017; Markowitz & 
Perazella, 2005; Naughton, 2008; Perazella, 2003; Singh et al., 2003). Loh and colleagues (2009) 
mention top ten categories of medications that cause kidney damage involving antibiotics, 
analgesics, COX-2 inhibitors, proton pump inhibitors, antiviral drugs, high blood pressure drugs, 
rheumatoid arthritis drugs, lithium, anticonvulsants, and chemotherapy drugs. The same set of 
drugs is mentioned, more or less, in the other related studies as well. Moreover, it is widely 
discussed in the medical literature that diabetes is the leading cause of renal failure so that 
diabetic nephropathy (a.k.a. diabetic kidney disease) is today well known as a progressive kidney 
disease due to longstanding diabetes type II (Afkarian et al., 2016; Loh & Cohen, 2009). The 
mechanism through which diabetes leads to the development of diabetic nephropathy is studied 
by several researchers (Fujita et al., 2014; Lehmann & Schleicher, 2000; Sun, Su, Li, & Wang, 
2013). Most of these studies highlight the role of high blood sugar levels as well as high blood 
pressure in damaging capillaries in the kidneys glomeruli. Given that, the general expectation 
from common diabetes drugs should be to attenuate damages to kidney through balancing the 
blood sugar, thereby decreasing the likelihood of developing acute renal failure. Prior research 
has investigated the confounding role of some of the frequently prescribed diabetes medications 
and reported inconsistent effects. For instance, while Fatourechi et al. (2009) mention a positive 
confounding effect for insulin therapy, Thomas et al. (2007) suggest an association between 
insulin therapy and reduced incidents of renal failure. In addition, infrequently prescribed 
diabetes medications rarely were studied for their potential confounding roles in developing renal 
failure. 
We apply an extended version of the Reps et al. framework to the longitudinal 
prescription records of a large group of diabetic patients to investigate the confounding (either 
attenuating or intensifying) role of common diabetic medications (including those infrequently 
prescribed ones) in those patients. Furthermore, we investigate whether those confounding roles 
20 
 
are stable across various prescription combinations or they might change due to potential drug-
drug interactions, thereby trying to explain inconsistent findings reported in prior research. 
Therefore, our research question is “How are the confounding roles of common diabetes 
medications in developing acute renal failure in diabetic patients? Are these roles stable for each 
drug across various prescription combinations?” 
2.3. MATERIALS AND METHODS 
2.3.1. MATERIALS 
In order to address the research question, we obtained data from a longitudinal observational 
electronic health records database, namely the Cerner HealthFacts data warehouse 6 
(http://www.cerner.com). Cerner HealthFacts is the most comprehensive relational database in the 
U.S. and contains complete medical records of more than 63 million unique patients across the 
country. The database contains time-stamped entries of patients’ visits, physicians’ diagnoses, and 
prescribed drugs (among other patient-event specific characteristics). Prescription and diagnosis 
records of adult patients (18 or older) diagnosed with diabetes mellitus (ICD9- 250) for the first 
time during the 4-year period of study (i.e., 2012-2015) were extracted for analysis. The initial data 
involved 377,910 unique patients. Since the focus of our study was on diabetic drugs as well as 
kidney-damaging (KD) drugs, we then filtered the prescription records to keep only these types of 
drugs for analyses. 
2.3.2. METHOD 
A case-control design was employed to conduct the analyses. In this design, the case group were 
those diabetic patients who developed acute renal failure (ICD9- 580) during the study period, 
                                                     
6 Cerner is not a publicly available data source, however, the authors had access to that via their institution, 
to which the data warehouse is donated for the research purposes.  
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and the control group involved those diabetic patients who were not diagnosed with renal failure 
by the end of the study period. 
For each patient identified as a case subject, we considered two index dates; 1) the date 
he or she was diagnosed with diabetes mellitus for the first time, and 2) the date the patient was 
diagnosed with renal failure for the first time. Two subjects were matched as the control to each 
case-patient by matching on their age, race, gender, comorbidities and the first index date (i.e., 
the date he or she was first diagnosed with diabetes mellitus). Moreover, the second index date 
for each control is the same as its matching case’s second index date. Matching two controls for 
each case-patient makes the sample more representative of the population (Reps et al., 2016). An 
innovative method was used to match the controls to each case patient, in which we coded each 
patient profile using an ten-character string including two characters for age, one character for 
gender (male=1, female=2), one character for race (Caucasian=1, African-American=2, 
Hispanic=3,...), two character for comorbidities, and four characters for a numeric transformation 
of the first index date (indicating the number of days passed since January 1, 2000). We then used 
a simple SQL query using the coded patients profile to find all the matches from the potential 
control patients to each subject in the case group and randomly selected two of them for each case 
subject. Since there were less than two matches for some case subject profiles, we re-coded the 
profiles for that particular patients and replaced the four-digit index date with a three-digit one 
representing the number of weeks passed since January 1, 2000 and ran the queries again. There 
were also some cases for which we used the month of the index date to find a matching. 
However, fortunately, there was no problem with regard to finding matches in terms of any of the 





Table 2.1. Profile of D1 and D2 databases 
Gender Race Age Comorbidities 
Male  55.76% 
Female 44.24% 
Caucasian  47.21% 
African-American  41.22% 
Native American  2.66% 
Hispanic  2.61% 
Asian  1.04% 
Other  5.26% 
Mean   40.77 
StDev   7.51 
Mean   5.38 
StDev   2.15 
 
In the next step, two databases were created. D1 which involved the prescription records 
pertaining to the last 10 visits prior to the second index date of patients in the case-group 
(including 1,294 patients); and D2 containing the same information for their corresponding 
control patients (2,588 patients). In order to construct the databases, if a drug was prescribed two 
or more consecutive times, we only kept the earliest prescription. Also, all the medications 
prescribed in a single visit were given the same sequence label. Given these assumptions, we 
came up with 18,562 and 22,388 prescription records for the case and control patients, 
respectively. Table 2.1 demonstrates the profile of the two databases in terms of the factors the 
patients were matched on. 
To investigate the potential confounding role of diabetic drugs we then applied frequent 
itemset mining, using the association rule mining pre-defined procedure in SAS Enterprise Miner, 
to both D1 and D2 to identify frequent sets of drugs along with their support (i.e. the proportion 
of transactions in the database that contain that set of drugs). Frequent itemset mining is a branch 
of frequent pattern mining in which the focus is on identifying sets of items within a transactional 
database that appear sufficiently often in the whole database. Therefore, a support threshold 
should be determined by the user to specify for the algorithm as to "how often" do we consider 
"sufficiently often". One of the popular algorithms for extracting frequent itemsets from a 
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transactional database, used as the main algorithm in the SAS Enterprise Miner platform, is the 
Apriori algorithm proposed by Agarwal and Srikant (1994). The algorithm begins by identifying 
frequent single items in a transactional database, and then in each subsequent iteration generates 
candidate itemsets of size n from the itemsets of size n-1 and then prunes the infrequent 
candidates with regard to the given support threshold. Even though recently multiple innovative 
algorithms and metrics have been proposed for effective association rule mining under special 
circumstances or with different approaches such as incomplete evidence (Galárraga, Teflioudi, 
Hose, & Suchanek, 2013), in the presence of constraints (Baralis, Cagliero, Cerquitelli, & Garza, 
2012), identifying rare rules (Piri et al., 2018), using utility-based (as opposed to frequency-
based) mining (D. Lee, Park, & Moon, 2013), and taking into account the weight of items in the 
rule mining (Vo, Coenen, & Le, 2013), yet Apriori is known as an effective generic association 
rule mining algorithm.  
In order to find more relevant itemsets, we limited the maximum size of itemsets to 5 and 
the minimum support threshold to 0.5% in both data sets. The reason we limited the maximum 
size of itemsets to 5 is that the average number of transactions (i.e., distinct medications 
prescribed) for the patients in the control group was 5.10 with a median of 5; therefore 
considering itemsets including less than 5 drugs would result in excluding half of the control 
patients (probably the healthier half) from the analyses and would make the results biased. In 
addition, given the total number of patients in the case and control groups, considering a support 
threshold less than 0.5% technically was pointless, since it would result in very small frequencies 
and the corresponding itemset most probably would not suggest any statistically significant 
results. It should be noted that we did not take into account the sequence in which the drugs were 
administered (i.e., a non-sequential itemset mining analysis was done). Hence, for instance two 
itemsets like {a,b,c} and {c,a,b} were considered equivalent in calculating supports. 
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At the end of this process, we come up with a list of itemsets for each group of patients 
along with their support in their corresponding databases. At this stage, the itemsets containing 
both types of drugs of interest (i.e. diabetic and KD) were identified to focus on. We call them 
Combined Sets (CS) from now on. For each itemset in the CS, we then find matches from 
itemsets including all its KD drugs, but no diabetic drugs. We call this second group Pure Sets 
(PS). Hence, for each itemset in the CS, there are one or more matches in the PS. For example, if  
M={acetaminophen, vancomycin, insulin} is a frequent itemset identified as CS, its matching set 
in the PS would be M’={acetaminophen, vancomycin} which only involves drugs from KD 
category (note that M’⸦ M). The CS and PS itemsets were identified in both case and control 
patients. 
In the medical literature, Relative Risk (RR) is a measure used to indicate the risk of 
developing disease given exposure to its causes (Altman, 1990). Suppose that we expose the case 
group to a particular factor while keeping the control group unexposed. If we record the number 
of bad and good outcomes in each group (let’s call them a and b for the case and c and d for the 






                                                             (Eq.1) 
With the standard error of the log RR being: 












                                     (Eq.2) 
In this study, since the outcome of interest (i.e. renal failure) was an ADR, and the goal 
was to identify the potential confounding effect of diabetic drugs, then each diabetic drug was 
considered as a potential cause for the outcome. Let us consider the case group in our study first. 
If we call the number of patients having a particular CS itemset (Ics) in their prescription records 
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“a”, and the number of case patients having the PS itemset (Ips) corresponding to Ics (note that 
𝐼𝑝𝑠 ⸦ 𝐼𝑐𝑠), "b", then 
𝑎
𝑎+𝑏
 would represent the ratio of case patients who were exposed to the 
diabetic drug involved in Ics (i.e., Ics-Ips) to the case patients who have taken both diabetic and 
kidney damaging drugs involved in Ics . Similarly, 
𝑐
𝑐+𝑑
 can be interpreted as the same ratio in the 
control group of patients. Therefore, we argue that if this ratio for the case patients is significantly 
greater than for the control patients, it suggests that controlling for a particular PS itemset (Ips), 
prescribing a particular diabetic drug (i.e. Ics - Ips) generally increases the risk of renal failure (i.e. 
positive confounder). Conversely, if this ratio for the case patients is significantly smaller than 
that for the control patients, it suggests the corresponding diabetic drug is a negative confounder 
in developing renal failure. Finally, if the ratios are not different across two groups it suggests 
that the corresponding diabetic drug has no confounding role in developing renal failure. To make 
the risk ratio equation more meaningful for our particular purpose, we call it the confounding 
coefficient (CC) from this point on and we attribute it to the specific diabetic medication that 






                                                         (Eq.3) 
for a specific diabetic drug “X” is significantly (i.e., p-value<0.05) greater than 1, it suggests that 
the diabetic drug X is a positive confounder of the ADR (i.e., increases the risk of renal failure), 
since it is taken by the case patients significantly more than the control patients. Similarly, if 
CCdrugX is significantly (i.e., p-value<0.05) less than 1, it suggests that drug X is a negative 
confounder of the ADR (i.e., decreases the risk of renal failure) since it is taken by the case 
patients significantly less than by the control patients. In addition, a non-significant CC (i.e., p-
value>0.05) suggests no confounding role for the corresponding drug. Moreover, the 
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larger/smaller significant CC values suggest a potentially stronger positive/negative confounding 
effect. 
Table 2.2. A numerical example of the proposed method 
Ics Case Ctrl Ips Case Ctrl CCdrg050 p-value 
a c b d 
{drg050,drg230, drg344} 39 57 {drg230,drg344} 0 12 1.20 0.0005 
 
Table 2.2 indicates an example. Suppose that drg050 is a diabetic drug and drg230 and 
drg344 are two kidney-damaging drugs. The combined itemset including these drugs (𝐼𝑐𝑠) is 
identified as a frequent itemset. Excluding drg050, the diabetic drug, from this itemset we get an 
itemset purely including kidney-damaging drugs (i.e. 𝐼𝑝𝑠). Suppose that 39 case patients had all 
the three drugs in their prescription records (i.e., a=39). Also that the number of case patients 
having only the two kidney-damaging drugs but not the diabetic drug in their records was 0 (i.e., 
b=0). Similarly, suppose that these numbers in the control group are c=57 and d=12. The 






= 1.20                (Eq.4) 
with a p-value=0.0005. It suggests that the diabetic drug, drg050, is a positive confounder that, if 
prescribed along with drg230 and drg344, can increase to the risk of developing renal failure 
mainly caused by the other two drugs. 
Similar analyses were performed for all the identified frequent combined sets of drugs and their 
corresponding pure sets in both case and control groups of patients and the confounding 
coefficients were calculated multiple times for each common diabetic drug. The results were then 
integrated, as reported in section 4. Figure 2.1.  illustrates the method and procedures in a 




Figure 2.1. A graphical depiction of the data preprocessing and method development 




To conduct this research, we particularly focused on 23 common diabetic as well as 43 kidney-
damaging medications that were prescribed at least once for a patient in our initial data set. 
However, after identifying the case and control groups the numbers decreased to 16 and 31 
respectively, as some drugs were not prescribed for the patients in these groups at all. 
Applying frequent itemset mining to the prescription records of the case and control 
groups, more than 5,000 frequent itemsets (not necessarily unique) were identified using SAS 
Enterprise Miner. As noted before, we limited our rule extraction procedure to find itemsets 
including up to 5 drugs with a minimum support of 0.5% across the whole data set. We then 
filtered the frequent itemsets to include only the itemsets involving at least one drug of each type. 
This resulted in 246 unique frequent itemsets, which were, in fact, our Combined Sets (CS) of 
drugs discussed in the method section. Then for each of the CS itemsets, a subset containing only 
their corresponding kidney-damaging drugs was created; in our method terminology, we called 
these subsets the Pure Sets (PS). In the next step for each CS itemset and its corresponding PS, 
using the frequency of their incidence within the case and control patients’ prescription records, 
we calculated the CC associated with the diabetic drug involved in each CS itemset. 





Table 2.3. A sample of frequent itemsets and CC calculations 
Ics Case Ctrl Ips Case Ctrl CC p-value 
a c b d 
{insulin & acetaminophen & 
pantoprazole & aspirin} 
173 107 {acetaminophen & 
pantoprazole & aspirin} 
3 6 1.03 0.126 
{insulin & acetaminophen & 
ketorolac & aspirin} 
76 69 {acetaminophen & 
ketorolac & aspirin} 
1 11 1.14 0.004 
{pantoprazole & insulin & 
ketorolac & aspirin} 
46 36 {pantoprazole & ketorolac 
& aspirin} 
0 6 1.16 0.141 
{ketorolac & insulin & 
ibuprofen & acetaminophen} 
39 57 {ketorolac & ibuprofen & 
acetaminophen} 
0 12 1.20 0.0005 
{pantoprazole & metformin & 
acetaminophen} 
38 64 {pantoprazole & 
acetaminophen} 
330 208 0.44 0.0001 
{ketorolac & aspirin & 
metformin & acetaminophen} 
19 33 {ketorolac & aspirin & 
acetaminophen} 
58 47 0.60 0.032 
{insulin & ciprofloxacin & 
esomeprazole} 
24 16  {ciprofloxacin & 
esomeprazole} 
1 0 0.96 0.317 
{sitagliptin & acetaminophen & 
esomeprazole} 
9 10 {acetaminophen & 
esomeprazole} 
35 106 2.37 0.042 
{glyburide & aspirin & 
acetaminophen} 
10 0 {acetaminophen & aspirin} 352 326 18.91 0.042 
 
Table 2.4 shows a summary of results for the diabetes medications emerged in the 
frequent itemsets. As shown, from 16 common diabetic drugs involved in the case and control 
patients’ records, only nine emerged in frequent itemsets. For each of them, the table indicates the 
number of times they were present in distinct frequent itemsets as well as the number of times 
they were recognized as a significant (either positive or negative) confounder (using a 0.05 
significance level). For instance, for insulin (and its variations such as insulin aspart, insulin 
glargine, etc.), the results show that due to high frequency of its prescription for diabetic patients, 
it was present in 94 out of 246 identified frequent itemsets; from which, our analysis showed that 
in 53 itemsets insulin plays a significant confounding role. That is its corresponding confounding 
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coefficient (CC) was significantly different from 1. Among those significant cases, it was 
revealed that in 48 cases (90.6%) insulin plays a positive confounding role (i.e. CC>1). This 
suggests that controlling for the KD drugs present in each itemset, diabetic patients who 
experienced renal failure during the study period (i.e., case group) had been prescribed insulin 
significantly more frequently than those in the control group who did not experience the adverse 
outcome. Overall, it suggests that generally, insulin plays a positive confounding role in the 
development of renal failure in diabetic patients. As shown in Table 2.4, from the 9 drugs 
analyzed, only Metformin, Linagliptin, and Pioglitazone showed a generally negative 
confounding behavior and other diabetic medications exhibited a positive role in confounding the 
issue. 

























Insulin 94 53 48 (90.6%) 5 (9.4%) 1.10 1.23 0.91 Pos. conf. 
Metformin 52 38 0 (0%) 38 (100%) 0.52 0.71 0.26 Neg. conf. 
Glipizide 21 14 14 (100%) 0 (0%) 2.12 2.73 1.81 Pos. conf. 
Sitagliptin 18 11 9 (81.8%) 2 (18.2%) 4.38 6.15 0.93 Pos. conf. 
Glimepiride 18 8 8 (100%) 0 (0%) 3.61 5.61 2.10 Pos. conf. 
Glyburide 13 7 7 (100%) 0 (0%) 14.36 18.91 12.11 Pos. conf. 
Acarbose 11 7 6 (85.7%) 1 (14.3%) 3.09 3.76 0.97 Pos. conf. 
Linagliptin 11 6* 1 (16.6%) 5 (83.3%) 0.71 1.09 0.57 Neg. conf. 
Pioglitazone 8 4* 0 (0%) 4 (100%) 0.82 0.86 0.76 Neg. conf. 
* For these cases, significance was assessed at 0.1 level due to the scarcity of them among records. 
 
In order to make sure that the 0.5% support threshold used to identify the frequent 
itemsets was a proper choice, we looked into the number of frequent itemsets identified (for 
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insulin and metformin) as well as those in which the focal diabetes drug turned out as a 
significant confounder, considering four different thresholds ranging from 0.2% through 1.5% 
(see Figure 2.2). As shown in Figure 2.2 while in case of each drug both numbers increase by 
decreasing the support threshold, the gap between the two lines is considerable going from a 
0.5% down to 0.2% threshold. This actually happens since itemsets with a support less than 0.5% 
are such infrequent that using their frequencies in calculating the CC index for the corresponding 
diabetes drug does not result in a CC significantly different from 1. Overall, this confirms that 
0.5% seems to be a reasonable choice for support threshold, because thresholds lower than that 
technically does not provide us with considerably more information with regard to the 
confounding roles.  
  
Figure 2.2. Evaluating different support thresholds for identifying frequent 
itemsets 
Even though our analyses identified the dominant type of confounding role for each 
diabetic drug mentioned in Table 2.4, the results in this table also suggest that these confounding 
roles are not stable since for most of these diabetic drugs there exist frequent itemsets indicating 
significant confounding coefficients in the opposite direction as well. For instance, although 
insulin was said to be a generally positive confounder, our results indicate there were five 
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acute renal failure has been identified. In addition, this drug has not shown any significant 
confounding role at all in around 44% of the frequent itemsets in which it emerged. This suggests 
a very important point; that while insulin generally contributes to the development of acute renal 
failure, its confounding role varies depending on its potential interaction with other drugs 
administered to the patient. Table 2.5 indicates the five itemsets for which insulin turned out as a 
significant negative confounder. Our further investigation revealed that ciprofloxacin and 
sulfamethoxazole-trimethoprim, the two kidney-damaging drugs that are present along with 
insulin in these itemsets are not present in any of the itemsets that show a significant positive 
confounding role for insulin. This may suggest DDIs between these drugs leading to lower 
chances of developing renal failure. 
Table 0.5. Itemsets indicating a negative confounding role for insulin 
Itemset CCinsulin p-value 
{sulfamethoxazole-trimethoprim & insulin & aspirin & acetaminophen} 0.93 0.031 
{sulfamethoxazole-trimethoprim & insulin & aspirin & acetaminophen} 0.93 0.015 
{vancomycin & acetaminophen & sulfamethoxazole-trimethoprim & insulin} 0.91 0.019 
{aspirin & insulin & ciprofloxacin} 0.96 0.038 
{insulin & ciprofloxacin & acetaminophen & esomeprazole} 0.95 0.025 
Additionally, looking into the magnitude of average CC values for the diabetic drugs in 
Table 2.5, it suggests that Glyburide has the strongest positive effect (avg CC= 14.36) on 
increasing the likelihood of renal failure in diabetic patients, followed by Sitagliptin (avg 
CC=4.38). On the other hand, the average CC values for Metformin (0.52) and Linagliptin (0.71) 
implies that these two common diabetic drugs have the most negative confounding effect on the 




2.5. DISCUSSION AND CONCLUSIONS 
We extended an existing data mining framework in a case-control setting to investigate the 
potential confounding role of drugs with regard to a given adverse event. The extended 
framework was applied to the prescription records of a group of diabetic patients to investigate 
the potential confounding role of common diabetes medications (as well as its stability across 
various prescription combinations) in the development of acute renal failure (as the adverse event 
of interest in this study).  
The results indicate statistically significant differences between the prescription records 
of the case and control groups with regard to several common diabetic medications. Particularly, 
for the two most common medications for diabetes Type II patients (i.e. insulin and metformin), 
the results suggest potential generally positive and negative confounding roles for them, 
respectively. That is, controlling for the drugs already known to be associated with renal failure, 
the proportion of case patients prescribed with insulin was significantly higher than control 
patients. Similarly, the proportion of case patients prescribed with metformin was significantly 
lower than those in the control group.  
While insulin therapy is today a popular treatment among diabetic Type II patients due to 
its effectiveness in quickly reducing blood glucose level and positive effects on appetite and 
letting them have a more regular life, prior research have shown that uncontrolled insulin 
injection leads to resistance of the body to insulin and ultimately affects kidney due to 
hypoglycemia resulted (Fatourechi et al., 2009; Iglesias & Diez, 2008). Metformin then can 
function as a complementary agent to increase the sensitivity of the body to insulin and make a 
balance in such situations. Also, prior research (Berhanu, Perez, & Yu, 2007; von Websky, 
Reichetzeder, & Hocher, 2013; Yamanouchi, 2010) suggests that adding linagliptin or 
pioglitazone to insulin therapy can prevent hypoglycemia due to the accumulation of insulin. Our 
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results confirm such roles for metformin, linagliptin, and pioglitazone as they came out as 
negative confounding factors with regard to kidney failure. This actually provides support for the 
validity of the results obtained by our proposed approach.  
While the confounding roles of insulin and metformin have been studied in the prior 
research, the findings in those studies are somewhat inconsistent. For instance, Thomas et al. 
(2007) suggest that intensive insulin therapy in critically ill adult patients is associated with 
reduced incidences of acute renal failure. Also, Hsu et al. (2017) have reported that metformin 
may have an adverse effect in the renal function in patients with diabetes Type II. Our results 
provide an explanation for such inconsistencies by highlighting the role of potential drug-drug 
interactions that may lead a drug to act in an unexpected way with regard to an adverse event. 
Moreover, this study provides insights with regard to the general confounding effects of some 
diabetes medications that are under-studied in the literature, due to their lower prescription 
frequency by the practitioners. 
Of course, the present study is essentially a signal detection study and does not imply any 
causal relationship between the drugs and the ADR under study. This can be considered as the 
first step in a regular drug safety research which should be followed by assessments from a 
biological and clinical perspective and in-depth investigation to confirm or reject signals using 
expert opinions and randomized controlled trials (Shetty & Dalal, 2011). Future research may 
also validate and extend our approach by employing it for studying confounders of other common 
ADRs. 
Another contribution of this study is expanding a method originally proposed by Reps et 
al. (2016) for identification of drug-drug interactions (DDIs) involving more than two drugs. 
While there has been a huge amount of research on detecting DDIs involving pairs of drugs, in 
practice a typical patient might be prescribed with several drugs in each visit. Hence, taking into 
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account larger sets of drugs can help to reveal more reliable signals than when only two drugs are 
analyzed at a time. Again, further research should be conducted in order to assess and confirm the 
detected DDIs from the biological and clinical points of view.  
In short, our results indicate that while a general, either positive or negative, confounding 
role can be attributed to each of the common diabetic medications that holds in most of the 
prescription combinations, however, these confounding roles are not stable across various 
prescription combinations and taking into account drug-drug interactions sometimes a significant 
positive confounder may act as a negative one, or vice versa. This actually explains the 
inconsistent confounding roles reported in the literature and highlights the importance of 
considering DDIs in determining the outcome of a drug prescription.  
Of course, this research involves some limitations. Even though we controlled for the 
total number of comorbidities as a measure of general wellness, we did not control for the 
specific comorbidities between case and control groups as it would have significantly reduced the 
sample size and the power of analysis. In fact, we assumed that controlling for the age, gender, 
total number of comorbidities and the time of being diagnosed with diabetes, we can expect the 
same level of health between case and control patients regardless of their specific diseases. In 
addition, assuming that frequency of prescription of a drug has a strong correlation with the 
number of doses taken and given that this frequency leads to the emergence of the drug in the 
frequent itemsets, we also did not control for the doses of medications. These issues can be 
addressed in a randomized controlled trial study aimed at confirming the validity of signals 
detected here. So future research may expand the proposed approach by employing a larger data 
set (i.e., a wider study period) which allows for controlling the effect of specific diseases as well. 










ESSAY II: EXAMINING THE EFFECT OF PRESCRIPTION SEQUENCE ON DEVELOPING 




Objectives: While the effect of medications in development of Adverse Drug Reactions (ADRs) have been 
widely studied in the past, the literature lacks sufficient coverage in investigating whether the sequence in 
which [ADR-prone] drugs are prescribed (and administered) can increase the chances of ADR 
development. The present study investigates this potential effect by applying emergent sequential pattern 
mining techniques to electronic health records. 
Materials and Methods: Using longitudinal medication and diagnosis records from more than 377,000 
diabetic patients, in this study, we assessed the possible effect of prescription sequences in developing acute 
renal failure as a prevalent ADR among this group of patients. Relying on emergent sequential pattern 
mining, two statistical case-control approaches were designed and employed for this purpose. 
Results: The results taken from the two employed approaches (i.e. 76.7% total agreement and 68.4% 
agreement on the existence of some significant effect) provide evidence for the potential effect of 
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prescription sequence on ADRs development evidenced by the discovery that certain sequential patterns 
occurred more frequently in one group of patients than the other. 
Conclusion: Given the significant effects shown by our data analyses, we believe that design and 
implementation of automated clinical decision support systems to constantly monitor patients’ medication 
transactions (and the sequence in which they are administered) and make appropriate alerts to prevent 
certain possible ADRs, may decrease ADR occurrences and save lives and money. 
Keywords: Adverse Drug Events; Adverse Drug Reactions; Prescriptions Sequence; Emergent Pattern 
















Today every drug produced and marketed by pharmaceutical companies has a list of likely side effects 
printed on its label to warn patients about possible harms they may undergo by taking it. Such known side 
effects are usually the result of several years of research and clinical trials conducted on the drug by the 
manufacturer after discovery and before introducing it to the market. 
There are, however, some limitations involved in these clinical trials. They are often conducted 
over short timeframes and involve only a limited sample size. Therefore, the sample may not fully 
represent the population of consumers and may exclude patients who receive other medications. In 
addition, they are focused only on a particular group and usually exclude patients with complicated 
medical conditions (Karimi et al., 2015; Zeng et al., 2002). Moreover, these trials may not detect drug 
reactions with very low incident rates (Stephens & Talbot, 1985). Due to these shortcomings, the side 
effects of a considerable number of drugs are often only revealed in the post-marketing stage.  
In pharmacovigilance7 terminology, Adverse Drug Event (ADE) is a general term that refers to 
any injury caused by a medication. This injury can be an unintended effect of the recommended (i.e. 
prescribed or labeled) usage of a drug, the off-label use of a drug, or a medication error (Karimi et al., 
2015). Adverse Drug Reactions (ADRs) are a subset of ADEs referring to an unexpected harm caused by 
the normal use of medication at the normal dosage (Karimi et al., 2015). Therefore, ADRs do not have to 
be related to the non-prescribed or off-label usage of a drug or medication errors; instead, they are 
generally the result of unexpected drug-event or drug-drug interactions. ADRs are reported by Australian 
Commission on Safety and Quality in Healthcare (ACSQHC, 2012) to cause about 400,000 visits to 
general practitioners and about 190,000 visits to hospitals in each year in Australia with a population of 
                                                     
7 Pharmacovigilance (a.k.a. drug safety surveillance) is a field of science that tries to detect, assess, understand, and 
prevent harms and injuries caused by medications in all stages of drugs’ lifetime (i.e. discovery, clinical trials, pre-
marketing, and post-marketing). (World Health Organization) 
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only 23 million people. Also, the cost incurred by each ADR case in community hospitals in the United 
States is estimated at $3,000 (Classen et al., 1997; Hug et al., 2012). 
Such considerable costs to patients, insurance agencies, and the healthcare industry have caused 
researchers to seek effective ways for detection, prediction, and prevention of ADRs during the past 
years. Multiple approaches are employed for this purpose and information systems (IS) have been playing 
a key role in almost all of them so that the main three ones, namely Spontaneous Adverse Drug Reporting 
Systems (SAERS), analysis of Electronic Health Records (EHR), and analyzing Social Media feedbacks 
are all heavily relied on information systems. 
An important potential factor in the occurrence of adverse drug reactions is the sequence by 
which the drugs are administered. Although this potential factor is mentioned in prior research to be more 
investigated (Egger, Drewe, & Schlienger, 2003), to the best of our knowledge, no prior research has 
empirically investigated the effect of this factor on the likelihood of ADR development. Hence, the main 
aim of our study is to investigate the potential effect of the prescription sequence on the development of 
adverse drug reactions. One of the five most common ADRs identified in the literature is acute renal 
failure8 (Trifirò et al., 2009). The literature has identified several drugs with renal failure as one of their 
side effects (Härmark et al., 2007; Perazella, 2003; Perneger, Whelton, & Klag, 1994; Singh et al., 2003). 
Due to its importance and high potential risk, in this study we specifically focus on this particular ADR 
and investigate the possible effect of the prescription sequence of its corresponding causes on the 
likelihood of its development. 
To this end, we develop two independent approaches both using a case-control study design. 
First, a sequential emergent pattern mining approach is developed to compare the sequential prescription 
patterns between the case (those patients who developed a specific ADR) and control patients (those 
patients, matched to the case patients on various factors, who did not develop the ADR) with the aim of 
                                                     




identifying whether different sequential patterns of the same frequent set of drugs have different effects 
on the likelihood of developing the ADR. Second, we compared the rank order of various sequential 
patterns of each frequent set of drugs (identified using a frequent itemset mining algorithm) by the means 
of the Spearman rank order correlation to specify whether for each non-sequential frequent set of drugs, 
the frequency of sequential patterns is significantly different among the case and control patients. 
The remainder of this paper is organized as follows. In section 2, through a review of the 
literature, we discuss the role of IS in ADE detection, prediction, and understanding research as well as 
various approaches employed in prior research for this purpose. Next, in section 3, the research question 
will be explained in more details. Following that, in section 4, we introduce the data set and the data 
preparation processes used to investigate the research question. Also, the method of analysis is explained 
in the same section and it is followed by the results (section 5) and discussion (section 6) of theoretical 
and empirical implications. 
3.2. LITERATURE REVIEW 
It takes ten to fifteen years, on average, for a new drug to pass through the required clinical trials, get 
approved, and be introduced to the market (Iizuka, 2007). However, even after this long process it is 
unlikely that all the risks associated with taking a drug have been identified. It is particularly due to 
limitations involved in lab experiments. They are often short time experiments and involve just a limited 
sample size (Zeng et al., 2002); the samples do not fully represent the target population of the drug as 
may be focused on particular groups and exclude others (Karimi et al., 2015); and the reactions with very 
low incidence rates are hard to detect through clinical trials (Stephens & Talbot, 1985).  
These shortcomings have caused a considerable number of potential drug-drug and drug-event 




Adverse Drug Events is the general term in the Drug Safety Surveillance domain that refers to 
any injuries caused by a medication. An ADE can be described along several dimensions like the severity 
of its consequences, the stage of the medical use process in which it occurred, and the type of cause (e.g. 
medication error, wrong dosage, reaction with other drugs, etc.) (Riccioli, Leroy, & Pelayo, 2009). Since 
ADE by definition includes every kind of injuries (i.e. either due to a normal or abnormal usage of 
medications), a more specific definition is proposed in the literature for injuries specifically caused by 
normal use of medications at the normal, prescribed dosage. These type of unexpected causes are referred 
to as Adverse Drug Reactions (ADR) in pharmacovigilance terminology (Karimi et al., 2015; Nikfarjam 
et al., 2015a).  
Due to considerable costs and damages incurred by ADRs to the patients, insurance agencies, and 
healthcare providers, there has been a stream of research on detection, prediction, and understanding of 
this phenomenon in multiple disciplines including medicine, economics, and IS. The researchers in this 
area have employed various approaches, but what is shared among them is their heavy reliance on 
information systems for collection, extraction, and analysis of data required for detection and prediction 
of ADRs.  
As an effort to rapidly detect and take appropriate action to ADRs, many countries and 
organizations have run Spontaneous Adverse Drug Reporting Systems (SAERSs); information systems 
designed to allow patients and professionals to submit their reports of suspected adverse drug events. 
Some of the examples of such systems are the World Health Organization’s (WHO) Individual Case 
Safety Reports (ICSR) database, the Therapeutic Goods Administration’s (TGA) Adverse Drug Reaction 
System (ADRS) in Australia, the yellow card system of Medicines and Healthcare products Regulatory 
Agency (MHRA) in the United Kingdom, and the FDA Adverse Event Reporting System (FAERS) in the 
United States (Karimi et al., 2015).  
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Although spontaneous reporting systems have been the main source to detect likely ADR cases 
for years, they still have several limitations such as over-reporting of highly common ADRs, missing and 
incomplete data, duplicated reporting and voluntary submission (Harpaz et al., 2013). Due to voluntary 
submission of the reports, for instance, it is estimated that these systems in the US and UK reflect less 
than 10% of the adverse effect occurrences (Inman & Pearce, 1993; Yang et al., 2012). Such 
shortcomings led pharmacovigilance practitioners to look for resources that are more efficient for post-
marketing drug surveillance. 
In recent years, Electronic Health Records (EHR) have been widely used in the healthcare 
industry to help practitioners in the collection, storage, and tracking patients' information and their 
treatment progress. The vast amount of data collected by EHRs as well as their increasing availability 
have made them interesting resources for pharmacovigilance researchers and presented opportunities to 
investigate and detect ADR signals9 closer to real-time (Trifirò et al., 2009). Several data mining 
approaches have been proposed and applied by data scientists on EHR data in the past few years. Despite 
utilizing EHR data for pharmacovigilance purposes have gained much interest from European and 
Australian researchers, there is still a lack of sufficient research by the US academics and practitioners on 
the EHR data from the US healthcare market. Even though EHR data is generally more complete than 
data collected by spontaneous reporting systems, yet using EHR data for detection and prediction of ADR 
cases involves challenges such as complex data preprocessing requirements and various data 
documentation styles across different healthcare organizations (Harpaz et al., 2013).  
Social media has also been considered as a key data source for monitoring drugs’ post-marketing 
feedbacks in the recent few years by many researchers. A Pew internet research by Fox and Jones (2009) 
found that 61% of American adults look for health information (i.e. about specific diseases and 
treatments) online. This is normally done either through healthcare online forums such as ‘Ask a patient’, 
                                                     
9 In pharmacovigilance, a signal is defined by the WHO as information on a possible causal relationship between an 
adverse event and a drug, which is unknown or incompletely documented (Trifirò et al., 2009). 
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‘Dailystrength’, ‘Yahoo health and wellness’, and ‘PatientsLikeMe'; or through social networks like 
Facebook and Twitter. Through social media, people talk about their concerns, seek advice about their 
diseases and health issues, and discuss their experiences with the medications they take. Such 
information, although noisy, is likely to appear there long before it is reported to any SAERS or detected 
via EHRs. Most of the time, the topics discussed by patients in social media are the ones which they are 
reluctant to discuss with their doctor, especially those prescribed for serious conditions like cancer, where 
the patient can experience high levels of anxiety due to the long-term exposure to the drugs (Benton et al., 
2011; Leaman et al., 2010).  
Due to these facts, many researchers have started to use social media for ADR detection and 
prediction purposes. Particularly Twitter as an open-access social network is used in several drug 
surveillance studies and several text-mining and sentiment analysis approaches were developed to identify 
patterns and signals of drug-event relationships (Bian, Topaloglu, & Yu, n.d., 2012; Culotta, 2010; Ginn 
et al., 2014; Nguyen et al., 2017; Prier et al., 2011). Apart from tweets, some researchers have also 
analyzed people’s comments in public healthcare forums mentioned above for the same purpose (Karimi 
et al., 2011; Leaman et al., 2010; X. Liu & Chen, 2013). Yet it seems that this field of research is still in 
its infancy period and calls for a lot more work. 
3.3. RESEARCH QUESTION 
In terms of the research goals, pharmacovigilance studies can be classified into three categories, namely 
detection, prediction, and understanding studies (Davazdahemami & Delen, 2018). Detection studies 
mainly aim at detecting existing associations (i.e., signals) between drugs and potential adverse reactions, 
often by analyzing historical usage data obtained from various resources. Prediction studies are those that 
utilize information about already known drug-ADR associations to predict possible ADRs for newly 
discovered as well as existing drugs. While detecting and predicting potential associations is a critical 
task, it is clear that such associations do not hold all the time and in the case of every patient. That is why, 
for instance, a particular patient might experience a side effect of a given drug, while that drug may not 
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have any adverse effect in another patient. Hence, it is crucial to investigate and understand the 
mechanism through which drugs develop side effects in the patients by identifying factors that either 
intensify or mitigate the strength of a drug-ADR association. This is, in fact, the goal of the understanding 
group of pharmacovigilance studies. 
Prescription sequence, the sequence by which the drugs are prescribed and administered, is one of 
the factors that is suggested in the literature (Egger et al., 2003) to be investigated for its potential effect 
on the likelihood of ADRs development. To the best of our knowledge, no prior study has empirically 
investigated this potential effect, though. Hence, the research question we address in this study is: 
RQ: Does the sequence of drug prescription (and consequently drug administration) have any 
effect on the development of adverse drug reactions? 
3.4. MATERIALS AND METHOD 
3.4.1. MATERIALS 
In order to address the research question, we used a longitudinal observational electronic health records 
database, namely the Cerner HealthFacts data warehouse (http://www.cerner.com). Cerner HealthFacts 
data warehouse is the most comprehensive relational database in the US containing complete medical 
records of more than 63 million unique patients across the country. Cerner HealthFacts data warehouse 
contains time-stamped entries of patients’ visits, physicians’ diagnoses, lab tests, procedures, and 
prescribed drugs for both primary and secondary care visits. Prescription and diagnosis records of adult 
patients (18 or older) diagnosed with diabetes mellitus (ICD9- 250) for the first time during the 4-year 
period of 2012-2015 were extracted for analysis. The reason we limited our dataset to only diabetic 
patients was first to make the data more homogenous; and second the high rate of development of acute 
renal failure in this group of patients. The initial data involved prescription and visiting records of 
377,910 unique patients.  
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There is an event-based stream of research focused on investigating the drugs associated with 
kidney diseases in general, and acute renal failure in particular (Coca & Perazella, 2002; Davazdahemami 
& Delen, 2019; Izzedine et al., 2005; Markowitz & Perazella, 2005; Naughton, 2008; Perazella, 2003; 
Singh et al., 2003). Loh and colleagues (2009) mention top ten categories of medications that cause 
kidney damage involving antibiotics, analgesics, COX-2 inhibitors, proton pump inhibitors, antiviral 
drugs, high blood pressure drugs, rheumatoid arthritis drugs, lithium, anticonvulsants, and chemotherapy 
drugs. The same set of drugs is mentioned, more or less, in other related studies as well. Since the focus 
of our study was on the drugs previously revealed to cause damages to the kidney, we focused on a set of 
43 kidney-damaging medications from the top ten categories of drugs mentioned in the literature, and 
filtered the prescription records to retain only these class of drugs for analysis.  
3.4.2. METHOD 
In order to address the research question, we employed a case-control study design. In this design, the case 
group were those diabetic patients who developed acute renal failure (ICD9- 580) during the study period, 
and the control group involved those diabetic patients who were not diagnosed with renal failure by the end 
of study period. 
Emergent pattern mining is a type of association rule mining that is used to detect differences 
between databases. The goal of emergent pattern mining is to find itemsets that are more frequent in one 
database (i.e. the case group in our study) compared to another (i.e. the control group). 
For each patient identified as a case subject, we considered two index dates; 1) the date he or she 
was diagnosed with diabetes mellitus for the first time, and 2) the date the patient was diagnosed with renal 
failure for the first time. Two subjects were matched as control to each case-patient by matching on their 
age, race, gender, comorbidities and the first index date10. Moreover, the second index date for each control 
                                                     
10 In case we couldn’t match the controls who were diagnosed with diabetes on the same month and year, we 
searched through patients diagnosed in the months before or after the case’s first index date to find a match. 
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is the same as its matching case's second index date. Matching two controls for each case-patient makes the 
sample more representative of the population and leads to more accurate approximations of the support, as 
a measure of prevalence of drugs in the patients’ prescription records (Reps et al., 2016); it also does not 
cause any issues in comparison of the two groups as the comparison criterion is the support, which is a 
percentage in nature. The emergent pattern mining will find sets of drugs that are prescribed more often 
prior to the second index date for the case subjects compared to the controls. 
In short, two databases were created. D1 involves the prescription records pertaining to the last 10 
visits prior to the second index date of patients in the case group (including 1,294 patients) whereas D2 
contains the same information for their corresponding control patients (2,588 patients).  
To investigate the potential effect of prescription sequence, we then applied frequent itemset 
mining to both D1 and D2 to identify both sequential and non-sequential frequent sets of drugs along with 
their support. Suppose Ins is an itemset (containing k distinct items) identified as frequent in a database. 
Consider Ins a non-sequential itemset in that the sequence of items (i.e. the sequence of drug 
prescription/administration) is not accounted for. Taking into account the sequence of items, then k! 
itemsets can be driven from Ins each with a unique sequence of items (i.e. sequential itemsets Is1, Is2, Is3, ..., 
Isk!). The non-sequential itemset Ins as well as all its corresponding sequential sets, each would have a 
support index indicating the proportion (and the number) of transactions (i.e. patients) involving them in 
each database. Given these notations, the two approaches we used to investigate the effect of drug taking 
sequence follow. 
The first approach is based on the Relative Risk notion. In the medical literature, Relative Risk 
(RR) is a measure used to indicate the risk of developing disease given exposure to its causes (Altman, 
1990). Suppose that we expose the case group to a particular factor while keeping the control group 
unexposed. If we record the number of bad and good outcomes in each group (let’s call them a and b for 
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With the standard error of the log RR being: 
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In this study, our goal is to evaluate the confounding role of the sequence factor. For a non-
sequential itemset (Ins), if a and c represent the number of its incidents within the case and control databases 
respectively; also b and d represent the number of case and control patients not having the itemset in their 
records, then Equation 1 would represent the relative risk associated with the itemset Ins. Therefore an RR 
greater than one would suggest that the itemset Ins is relatively more frequent in case patients than it is in 
control patients. Then it can be expected that someone having that itemset in his or her prescription records 
experience the negative outcome (i.e. ADR) more likely than someone who does not have it. The RR can 
be calculated for each of the possible sequential itemsets in a similar way. Having relative risk values for 
the non-sequential as well as the corresponding sequential itemsets, we argue that any inconsistency in 
these values implies the potential effect of the sequence factor. By inconsistency, we mean situations in 
which either one or more of the following conditions hold: 
1- The RR associated with a non-sequential itemset is significant whereas at least one 
of the corresponding sequential itemsets have non-significant RR value or vice versa. 
2- The RR associated with the non-sequential itemset is significant and greater than 
one (suggesting a positive confounding role for that itemset) whereas some of the corresponding 
sequential itemsets have significant values of RR that is less than one (suggesting a negative 
confounding role for that itemset).  
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3- The RR measures associated with both the non-sequential and sequential itemsets 
are significant and greater (less) than one, but they considerably differ in terms of magnitude. We 
considered a minimum difference of 0.5 in the magnitude of RR as the threshold as it suggests that 
the incidence of the corresponding sequential pattern is 50% more (or less) frequent than the non-
sequential pattern in the case patients compared with controls.  
We consider these conditions as inconsistency because they imply that patients experiencing the 
same set of drugs can have different likelihoods of experiencing the negative outcome depending on the 
sequence by which those drugs are prescribed/administered.  
Table 3.1 indicates an example to clarify this approach. It is shown that the relative risk when the 
sequence is not taken into account (i.e. RRns) is significantly greater than 1 whereas accounting for the 
sequences only the last three itemsets involve a significant relative risk. That is, administering the same 
drugs in some particular sequences poses a higher risk of developing the negative reaction than other 
sequences. 
The second approach relies on comparing the patterns of incidence of sequential itemsets across 
patient groups. Here the idea is that if the sequence of drug prescription has nothing to do with the likelihood 
of the negative outcome, then we should anticipate observing roughly the same pattern of incidence for 
sequential itemsets across the case and control groups. To compare these patterns, we first sort the 
sequential itemsets, separately in the case and control groups, according to their support in the 
corresponding databases and accordingly give a rank order to each itemset in each group. We then apply 
Spearman Rank Order Correlation to their ranks. A small, non-significant, or negatively significant 
correlation coefficient between the rank orders suggests that the pattern of incidence of the itemsets is 
different across the two groups of patients. In other words, some particular prescription sequences that are 
highly frequent among case patients are not so among the control group and vice versa.   
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An example is shown in Table 3.2. In this case, the rank order correlation for different sequences 
of an itemset in the case and control groups is non-significant. It suggests that the case and control patients 
have experienced different sequential patterns of the same itemset. It can also be realized by looking at the 
ranks of itemsets in the groups. For instance, sequential itemset {drg303, drg101, drg202} which is the 
most frequent pattern among case patients (i.e. rank=1), is the second least frequent pattern among control 
patients.  
Figure 3.1 indicates a summary of the methods and procedures. 
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Table 3.1. Example of the First Approach 
Non-sequential Case Control RRns 
(p-value) 
Sequential Case Control RRs  
(p-value) Ins a b c d Is a’ b’ c’ d’ 
{drg101,drg202,drg303} 91 1001 88 1462 
1.468 
(0.008) 
{drg101,drg202,drg303} 41 1051 46 1504 1.265 (0.2650) 
{drg101,drg303,drg202} 37 1055 37 1513 1.419 (0.1260) 
{drg202,drg101,drg303} 42 1050 41 1509 1.454 (0.0830) 
{drg202,drg303,drg101} 45 1047 26 1524 2.457 (0.0002) 
{drg303,drg101,drg202} 50 1042 30 1520 2.366 (0.0002) 
{drg303,drg202,drg101} 49 1043 37 1513 1.880 (0.0030) 
 
Table 3.2. Example of the Second Approach 
Itemset Case Control Spearman Rank Order 
Correlation 
Support (%) Rank Support (%) Rank 
{drg101,drg202,drg303} 3.755 5 2.968 1 
-0.55 
(p=0.257) 
{drg101,drg303,drg202} 3.388 6 2.387 3 
{drg202,drg101,drg303} 3.846 4 2.645 2 
{drg202,drg303,drg101} 4.120 3 1.677 6 
{drg303,drg101,drg202} 4.579 1 1.935 5 









Two data sets including prescription records of 1,294 case patients and 2,588 control patients 
were analyzed using the two developed approaches described.  Table 3. indicates the age, race, 
gender, and comorbidities in the cohorts. It should be noted that since the patients in the two 
groups were matched on all these four factors, the profile shown in this table is indicative of both 
case and control cohorts of patients.  
Table 3.3. The cohorts profile 
Gender Race Age Comorbidities 
Male  55.76% 
Female 44.24% 
Caucasian  47.21% 
African-American  41.22% 
Native American  2.66% 
Hispanic  2.61% 
Asian  1.04% 
Other  5.26% 
Mean   40.77 
StDev   7.51 
Mean   5.38 
StDev   2.15 
 
To conduct this research, we particularly focused on 43 kidney-damaging medications 
from the top ten categories of drugs mentioned in the literature that were prescribed at least once 
for a patient in our initial data set. However, after identifying the case and control groups that 
number decreased to 31 as some drugs were not prescribed even once for the patients in our data 
set. Additionally, since the study was focused on diabetic patients we also controlled for 16 
common medications that are frequently prescribed for those patients. That is, the identified 
frequent itemsets were filtered to only include known kidney-damaging and diabetic medications. 
The list of all medications included in the analyses is provided in Appendix 1.  
Also, Table 3. represents the top ten frequent medications in each group of patients along 
with their relative frequency. As shown, excluding the top four drugs, the frequency patterns of 
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prescriptions are different among the case and control patients so that, for instance, tacrolimus is 
among the top ten for the case group while it is ranked 15th in the control group. 
For each patient in either group, we then extracted all the prescriptions records of the 47 
medications of interest related to the last ten visits prior to the second index date of that patient. 
Each medication in the data set was labeled with a sequence number indicating the chronological 
sequence of visit/prescription. Therefore, if two drugs were prescribed in the same visit, they both 
had the same sequence label in the data set; also, In case a particular drug was prescribed in two 
or more subsequent visits, we considered the earliest visit for its sequence label. 
Table 3.4. Top frequent medication and their frequencies 














insulin (variations) Diabetic 1 9399 35.92 1 8259 34.76 
acetaminophen KD 2 4479 17.12 2 3936 16.57 
aspirin KD 3 2757 10.54 3 2229 9.38 
pantoprazole KD 4 2706 10.34 4 1839 7.74 
vancomycin KD 5 1071 4.09 8 765 3.22 
ketorolac KD 6 948 3.62 6 1272 5.35 
esomeprazole KD 7 777 2.97 9 528 2.22 
metformin Diabetic 8 513 1.96 5 1599 6.73 
tacrolimus KD 9 513 1.96 15 150 0.63 
ciprofloxacin KD 10 501 1.91 11 321 1.35 
Ibuprofen KD 11 498 1.90 7 1107 4.66 
glipizide Diabetic 12 309 1.18 10 381 1.60 
 
First, applying frequent itemset mining to the prescription records of the case and control 
groups, more than 5,000 frequent itemsets (not necessarily unique) were identified using the 
association rule mining predefined procedure (with non-sequential settings) in SAS Enterprise 
Miner. We limited our rule extraction procedure to only find itemsets involving up to 4 drugs 
with a minimum support of 0.5%. This resulted in 193 unique non-sequential frequent itemsets of 
size 4 or less. The reason we limited the size of itemsets to 4 was that for each non-sequential 
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itemset of size k we had to identify the k! sequential sets corresponding to that; hence an itemset 
of 5 would require us to identify 5!=120 sequential itemsets along with their supports whereas 
due to sample limitations most of those sequential patterns had not emerged in the prescription 
records whatsoever.  
Table 3.5. Top frequent co-occurrences of drugs 









{acetaminophen, insulin} 68.31 1 38.06 2 
{pantoprazole, insulin} 42.14 2 32.64 5 
{aspirin, insulin} 41.39 3 36.78 3 
{acetaminophen, pantoprazole} 33.70 4 35.10 4 
{aspirin, acetaminophen} 33.15 5 42.06 1 
{aspirin, pantoprazole} 19.96 6 19.22 9 
{ketorolac, insulin} 19.14 7 11.35 8 
{vancomycin, insulin} 17.31 8 9.61 9 
{ketorolac, acetaminophen} 16.12 9 13.29 6 
{ketorolac, insulin} 16.12 9 11.35 8 
{acetaminophen, vancomycin} 14.29 10 8.71 10 
{esomeprazole, insulin} 12.36 11 4.71 11 
{ibuprofen, acetaminophen} 9.34 16 13.03 7 
3 
{insulin, acetaminophen, pantoprazole} 32.97 1 16.32 2 
{insulin, aspirin, acetaminophen} 32.33 2 19.03 1 
{insulin, aspirin, pantoprazole} 19.41 3 8.84 6 
{pantoprazole, aspirin, acetaminophen} 16.12 4 7.29 10 
{acetaminophen, ketorolac, insulin} 15.75 5 11.35 4 
{vancomycin, insulin, acetaminophen} 13.92 6 8.13 7 
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{pantoprazole, ketorolac, insulin} 10.35 7 5.41 15 
{insulin, acetaminophen, esomeprazole} 9.52 8 4.71 19 
{insulin, acetaminophen, ibuprofen} 9.16 9 11.03 5 
{vancomycin, pantoprazole, insulin} 8.97 10 <0.5 NA* 
{acetaminophen, metformin, insulin} 7.69 18 13.16 3 
{aspirin, metformin, insulin} 4.58 27 7.74 8 
{aspirin, metformin, acetaminophen} 4.03 32 7.48 9 
*This itemset was not detected as a frequent one in the control group due to a support lower than the 
specified minimum of 0.5%. 
Table 3.5 contains the top ten non-sequential sets of medications (size 2 and 3) co-
occurred in the prescription records of the case and control groups along with their support within 
each data set. Again, there are remarkable differences in the frequency patterns as, for instance, 
while the set including aspirin and acetaminophen is the most frequent set (of size 2) in the 
prescriptions of the control group, it is ranked 5th among the itemsets corresponding to the case 
group. Similarly, whereas the set including vancomycin, pantoprazole, and insulin is among the 
top ten frequent sets (of size 3) in the case group, it was not even detected as frequent for the 
control group (given the minimum support threshold of 0.5%). These examples demonstrate 
considerable differences in the patterns of prescriptions between the two groups under study.  
The table indicates that while metformin was not within any of the top itemsets of size 2 
for either group, it was included in three of the top itemsets of size 3 (ranked 3rd, 8th , and 9th ) in 
the control group. From a clinical viewpoint, this fact suggests that probably metformin has to do 
with lowering the chances of developing renal failure in diabetic patients, since it was more 
frequently prescribed for patients in the control group, who ultimately did no develop renal 
failure during the study period. This confirms findings from prior research regarding metformin 
and its role in developing renal failure (Davazdahemami & Delen, 2019; von Websky et al., 2013; 
Yamanouchi, 2010). In addition, the relatively higher support (and rank) of itemsets including 
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insulin and/or pantoprazole in the case group suggests a potential enhancing role for these 
medications with regard to the risk of renal failure. For insulin, such a risk-enhancing role has 
been discussed in prior medical studies (Davazdahemami & Delen, 2019; Fatourechi et al., 2009). 
Of course, scrutinizing differences between these prescription patterns in more detail could 
provide us with more clinical insights regarding the role of diabetes and KD drugs in separation 
or together, in developing renal failure in diabetic patients. Nevertheless such a discussion is 
beyond the scope of the present study; in addition confirming each of those signals require a vast 
investigation of the medical literature and possibly conducting randomized clinical trials. 
At the next step, running the association rule mining procedure with a sequential rule 
setting in SAS Enterprise Miner, we obtained the frequency of incidence for the sequential 
itemsets, corresponding to the non-sequential sets identified earlier, across the case and control 
patients.  
Based on the frequency of each sequential itemset, we also ranked them in a descending 
order in both case and control databases. The frequency, as well as rank orders, were then used in 
the calculation of relative risk (RR) as well as the Spearman's rank order correlation (i.e. the two 
approaches explained in the methods section), respectively, for each of the 193 unique non-
sequential frequent itemsets. Finally, we applied the rules discussed in the methods section to 
determine whether in each case there is a considerable inconsistency between sequential and non-
sequential patterns across the two groups of patients.  
Table 3.6 illustrates a summary of our analyses using the two approaches. As shown, 
based on the RR criterion, we found that in 165 out of 193 itemsets (i.e. 85.5%) at least one of the 
three conditions for the significance of sequence effect was present. Also using the Spearman’s 
rank correlation, in 144 (74.6%) of the itemsets a considerable effect for the sequence of 
prescription was inferable. Interestingly, there were only 16 (8.3%) of cases in which none of the 
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approaches find enough evidence for the influence of prescription sequence in developing the 
adverse outcome. 
The table also shows the number of itemsets in which the conclusion about the influence 
of sequence was consistent or inconsistent. To test how the two approaches were consistent in 
terms of their conclusions, we conducted a chi-square test of independence on this 2x2 crosstab 
(i.e. Table 3.6). The outcome provides support for the consistency of the approaches (χ2 = 17.43, 
p<0.001).  
Table 3.6. Results 
RR                    
Influential Not influential Subtotal 
Influential 132 33 165 
Not influential 12 16 28 
Subtotal 144 39 193 
  
Overall, the results indicate that with respect to 68.4% of itemsets, both approaches 
agreed upon the existence of some significant effects that can be attributed to the sequence by 
which the medications were prescribed. Moreover, in 91.7% of itemsets, at least one of the two 
approaches revealed such an effect. 
3.6. DISCUSSION 
In this study, we investigated the potential effect of prescription sequence in the development of 
adverse drug events. While such potential effect had been mentioned in the literature, it was not 
empirically investigated prior to this study. To this end, using longitudinal transactional data 
obtained from the Cerner HealthFacts data warehouse and employing two independent 
approaches, we looked into the effect of the prescription sequence of 31 known kidney-damaging 




The results from each approach suggest a significant effect that can be attributed to the 
sequence by which the drugs were prescribed along the patients’ timeline. Moreover, it was 
shown that both approaches used to assess this effect are significantly in accordance with one 
another whereas they were designed independently and using different criteria. This suggests 
additional proof for the existence of such an effect. In fact, the two proposed approaches are the 
main theoretical contribution of the present study. Future research may employ the proposed 
approaches to assess similar sequential effects in other medical contexts. 
Also from an empirical viewpoint, we believe that the fact that sequence of prescriptions 
may result in developing adverse drug effects and intensify their probability suggests designing 
and implementing of new clinical decision support systems to help physicians in their 
prescription decisions by taking into account the patients' historical transactions and provide them 
with appropriate alerts to prevent possible ADRs.     
While we believe that our results strongly suggest a nontrivial effect attributable to the 
prescription sequence, yet of course we agree that our study involves some limitations. 
Particularly, even though we limited our sample to diabetic patients and controlled for their 
demographics, diabetes history, and common diabetic medications, still some important factors 
were not controlled due to sample limitations. Of the highest importance was the effect of 
patients' exact comorbidities that we did not control for in this study because doing such would 
greatly affect our sample size. It was not easy to find a control match for each case patient with 
exactly the same comorbidities. Hence, we limited this control to only a major disease which is 
highly prevalent among Americans (i.e., diabetes) and also controlled for the total number of 
comorbidities as a general measure of patients’ wellness. We also simply assumed that by 
controlling for age and other demographics we are also partly controlling for other particular 
comorbidities that might be attributable to aging. Future research may employ larger samples and 
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fully control for the effect of comorbidities. A larger sample also provides the possibility to 
include itemsets involving more than four drugs. 
It should be noted here that while the two independently designed approaches in this 
study consistently and strongly suggest a significant association between prescription sequences 
and ADR development, yet this association is not necessarily causal. In other words, our results 
provide a strong signal for the pharmacovigilance researchers to take the prescription sequence 
factor more seriously in their analyses and also justify conducting further studies in a more 
controlled environment to assess the causality of the detected association. 
In this study, we assumed that all the medications prescribed by doctors were 
administered by the patients until it was discontinued by their doctor again. In fact, it was not 
practically possible to monitor whether every drug had been administered as recommended. 
However, we believe that it is reasonably realistic to assume that medications prescribed in a 
particular visit were taken before those prescribed in the subsequent visit. Accordingly, instead of 
taking into account prescription timestamps we considered the timestamps of doctor visits as the 
base for sequence analysis. In other words, medications prescribed within the same visit were 
given the same sequence order, which was different from sequences of medications prescribed in 
the previous or subsequent visits. Future research may possibly address this limitation by using 
another source of data in which medication administrations were monitored. Finally, future 
research may improve the proposed approaches by taking into account the effect of drug dosages 
prescribed for the patients. 
In conclusion, it should be said that even though the present study is not perfect (makes 
certain assumptions and involves some limitations), because of the size and richness of the data 
used and the methods and measurement metrics developed and administered, its promising results 
might be considered as a promising baseline for deeper investigations on the effect of prescription 
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sequence as it possibly can prevent development of ADRs in millions of patients, improving their 
lives and wellbeing, and saving considerable amounts of money for them as well as for the 






ESSAY III: A CHRONOLOGICAL PHARMACOVIGILANCE NETWORK 
ANALYTICS APPROACH FOR PREDICTING ADVERSE DRUG EVENTS 
 
ABSTRACT 
Objectives: This study extends prior research by combining a chronological pharmacovigilance 
network approach with machine-learning techniques to predict adverse drug events (ADEs) based 
on the drugs’ similarities in terms of the proteins they target in the human body. The focus of this 
research, though, is particularly centered on predicting the drug-ADE associations for a set of eight 
common and high-risk ADEs. 
Materials and methods: A large collection of annotated MEDLINE biomedical articles were used 
to construct a drug-ADE network, and the network was further equipped with information about 
drugs' target proteins. Several network metrics were extracted and used as predictors in machine-
learning algorithms to predict the existence of network edges (i.e., associations or relationships).  
Results: Gradient boosted trees (GBT) as an ensemble machine-learning algorithm outperformed 
other prediction methods in identifying the drug-ADE associations with an overall accuracy of 
92.8% on the validation sample. The prediction model was able to predict drug-ADE associations, 
on average, 3.84 years earlier than they were actually mentioned in the biomedical literature. 
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Conclusion: While network analysis and machine-learning techniques were used in separation in prior 
ADE studies, our results showed that they, in combination with each other, can boost the power of one 
another, and predict better. Moreover, our results highlight the superior capability of ensemble type 
machine-learning methods in capturing drug-ADE patterns compared to the regular (i.e., singular), 
machine-learning algorithms. 


















Today every new drug to be approved by the healthcare authorities and marketed by pharmaceutical 
companies has to pass through numerous clinical trials, which on average take 10-15 years.(Iizuka, 2007)  
These clinical trials mainly aim at ensuring efficacy and safety of the drug. A considerable number of drugs 
fail to get US Food and Drug Administration (FDA) approval due to the potential threats their usage involve 
even though they might show effectiveness with regard to treating some specific diseases.(Trame, Biliouris, 
Lesko, & Mettetal, 2016) Nevertheless, even such tough regulations and approval procedures do not 100% 
guarantee the safety of a drug since those trials themselves involve several limitations and may fail to 
capture some potential, in some cases serious, safety issues (Karimi et al., 2015; Zeng et al., 2002).  
A classic example of such cases is Rofecoxib; an NSAID approved in 1999 that became highly 
welcomed by the physicians in a short time. The drug was originally aimed to treat acute pains and 
Osteoarthritis, but after a while turned out to cause heart attacks in more than 100,000 patients and ended 
up being withdrawn by the FDA in 2004. During that time, apart from the lives threatened, this possibly 
avoidable problem also imposed huge losses to pharmaceutical and insurance companies. 
Pharmacovigilance (a.k.a. drug safety surveillance) is a field of science that monitors the drugs 
during their lifecycle to detect, assess, and understand their potential adverse effects and prevent harms and 
injuries caused thereof. Although pharmacovigilance activities begin early after drug discovery, its role 
becomes more critical after drug approval, when humans start to take it. 
In pharmacovigilance terminology, an Adverse Drug Event (ADE) refers to any injury occurred to 
a patient caused by administering a drug. It should be noted that there is still no consensus on this 
terminology across pharmacovigilance and pharmacoepidemiology studies. Some studies(Nikfarjam, 
Sarker, O’Connor, Ginn, & Gonzalez, 2015b; Reps et al., 2016; Trame et al., 2016; Zeng et al., 2002) define 
ADE as any injury which not necessarily has a causal relationship with the drug (e.g., injuries due to human 
errors) and therefore use the more specific term Adverse Drug Reaction (ADR) to refer to the injuries 
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directly caused by the drug. However, in the present study, we stick with the term ADE while we emphasize 
that by ADE we mean a drug-induced (i.e. causally related) injury in patients. It is estimated that in the 
United States, each ADE case in community hospitals on average costs $3,000 (Karimi et al., 2015; Zeng 
et al., 2002). Also, ADEs are reported by the Australian Commission on Safety and Quality in HealthCare 
(ACSQHC) to cause about 400,000 admissions to general practitioners in Australia with a population of 
only 23 million.(Karimi et al., 2015) 
Given the great potential health and financial threats mentioned, and considering the fact that today 
the trend is toward faster approval processes and smaller clinical trials, especially in oncology and rare 
diseases(Trame et al., 2016), a great amount of research has been done in the past decade to find faster and 
more effective ways to detect, predict, understand, and prevent ADEs before they affect too many (or ideally 
any) people. 
In this study, we extend the extant literature on ADE prediction by proposing a chronological 
network analytics approach that can help pharmacovigilance practitioners to save lots of time, money, and 
more importantly, lives by enabling them to predict potential ADEs prior to drugs approval. The proposed 
approach uses historical information of known drug-ADE relationships in addition to similarities between 
new and approved drugs, in terms of the proteins they target in human bodies, and tries to predict potential 
ADEs. 
The remainder of this article is organized as follows; the following section reviews the extant 
literature on detection, prediction, and understanding of ADEs and states the research goals. Then, we 
explain the materials and methods used to conduct the study followed by the results. Finally, we discuss 




4.2.1. RESOURCES FOR ADE STUDIES 
Before discussing different approaches used in prior ADE studies, in this section, we discuss various data 
sources used by researchers to conduct those studies. Four main types of data source have been identified 
in the literature. The following four sub-sections introduce these resources and mention prior research 
conducted using each. 
4.2.1.1. Spontaneous Reporting Systems 
As an effort to rapidly detect and prevent ADEs in the post-marketing phase, many countries and 
international organizations have run Spontaneous Reporting Systems (SRSs); systems designed to allow 
patients and professionals to submit their reports of suspected ADEs. This includes the World Health 
Organization’s (WHO) Individual Case Safety Reports (ICSR) database, the yellow card system of 
Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, and the FDA Adverse Event 
Reporting System (FAERS) in the US.(Karimi et al., 2015) Although SRSs were the main source for ADE 
studies for several years, their limitations such as over-reporting and voluntary submissions(Harpaz et al., 
2013; Karimi et al., 2015) made pharmacovigilance practitioners look for more efficient alternatives.  
4.2.1.2. Electronic Health Records 
During the past decade, Electronic Health Records (EHR) have been widely used in the healthcare industry 
to help practitioners in the collection, storage, and tracking patients' information. The vast amount of data 
collected by EHRs along with their increasing availability have made them interesting resources for 
pharmacovigilance researchers and enabled them to detect ADE signals closer to real-time.(Trifirò et al., 
2009) Yet, using EHR data involves challenges like complex data preprocessing requirements and multiple 
standards across different databases(Harpaz et al., 2013). 
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4.2.1.3. Social Media 
 Recently social media has been introduced as a novel resource for conducting ADE as well as other 
healthcare studies. Virtual communities such as health forums (e.g., DailyStrength and PatientsLikeMe) 
and social networks (e.g., Twitter and Facebook) are places where people discuss their daily health-related 
experiences and concerns. Such information, although noisy, is likely to appear there long before it is 
reported to any SRS or recorded in any EHR(Benton et al., 2011; Leaman et al., 2010) and this has made 
social media a precious resource for early detection of ADEs. 
4.2.1.4. Biomedical Literature 
Recently, researchers have realized biomedical literature as well as chemical and biological databases as 
feature-rich sources for ADE studies. Databases such as PubMed, PubChem, KEGG, and DrugBank are 
rich sources of information about drugs, their chemical and biological characteristics, and their identified 
ADEs. 
4.2.2. ADE STUDIES: DETECTION, PREDICTION, AND UNDERSTANDING 
Due to considerable potential costs and damages of ADEs, in the past decades, there has been a great deal 
of research on this issue in many disciplines including pharmacology, economics, and information systems. 
While the ultimate goal of all of these studies is to identify drugs’ potential ADEs and prevent losses of 
lives and money thereof, they pursue different tools and strategies to achieve that goal. We believe that 
ADE studies can be classified into three distinct categories, namely detection, prediction, and 
understanding.  
Detection studies are the largest group of ADE research works focused on finding new and 
undetected ADE signals (i.e., associations, not necessarily causal) between the existent drugs (already in 
the market) and adverse events. The signals detected by these studies need to be assessed and verified by 
clinical trials. ADE detection studies heavily rely on applying statistical (Cai et al., 2017; van Puijenbroek 
et al., 2002) or data mining (Friedman, 2009; Harpaz et al., 2013; Harpaz, Chase, et al., 2010; X. Liu & 
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Chen, 2013; Nikfarjam et al., 2015b; Reps et al., 2016; Trifirò et al., 2009; Yang et al., 2012) methods and 
quasi-experimental settings to the historical data from SRSs (Cai et al., 2017; DuMouchel, 1999; Harpaz et 
al., 2013; van Puijenbroek et al., 2002), EHRs (Friedman, 2009; Haerian et al., 2012; Harpaz, Chase, et al., 
2010; Reps et al., 2016; Trifirò et al., 2009), or social media(Hoang et al., 2016; J. Liu et al., 2016; X. Liu 
& Chen, 2013; Nikfarjam et al., 2015b; Yang et al., 2012) to extract signals from them. 
In the ADE prediction studies, on the other hand, instead of detecting signals for the existent drugs 
using collected data from their past usage experiences, the focus is on creating signals for the new drugs 
before they cause any adverse events to the patients. The strategy in this group of studies is mainly to find 
similarities between the existent and the new drugs and thereby to predict ADEs for the new drugs given 
the already known relationships between their similar existent drugs with the corresponding ADEs. The 
statistical regression-based methods(Atias & Sharan, 2011; Cami et al., 2011) as well as machine learning 
techniques(L.-C. Huang, Wu, & Chen, 2011; L. Huang, Wu, & Chen, 2013; M. Liu et al., 2012) are the 
dominant methods used by the researchers for this purpose. Also in terms of data sources, prediction studies 
heavily rely on the biomedical literature as well as drug databases including chemical, physical, and 
biological information of drugs since such resources enable them to identify drug similarities. Just like ADE 
detection studies, this group of studies also serve as a signal detector, but the difference is they capture 
signals for new drugs as well.  
The last group of ADE studies in our taxonomy is those focusing on verifying ADE signals and 
understanding the mechanism through which the drug causes the ADE. Pharmacoepidemiology and 
pharmacometrics studies fall into this group as they use mathematical and parametric models of biology, 
pharmacology, and physiology to clarify and understand mechanisms of both beneficial and adverse 
molecular interactions.(Trame et al., 2016) Several different types of models have been used by the 
researchers in this group, among which Pharmakokinetics and Pharmacodynamics (Albrecht et al., 2017; 
Chiang et al., 2018; Lazaar et al., 2016; Vazzana et al., 2015; Wedemeyer & Blume, 2014) are the most 
popular modeling approaches. The former focuses on modeling how the organism affects the drug, whereas 
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the focus in the latter is on studying the effect of the drug on the organism; so the researchers usually employ 
them together, as the complement to each other to determine optimal dosing as well as the beneficial and 
adverse effect of drugs. In terms of data sources, this group of studies mostly rely on drug databases and 
EHR historical transactions.  
4.2.3. NETWORK ANALYSIS AND PHARMACOVIGILANCE 
Although Network Analysis (NA) have been widely used in many areas of science including sociology, 
communication, biology, economics, and computer science starting from a few decades ago, its application 
in pharmacovigilance studies is hardly older than 10 years. The main reason for that could be the lack of 
appropriate information systems and infrastructures for collecting the data required for constructing 
networks in large scale before the early 2000s. 
Networks have been used in pharmacovigilance research with a variety of data sources and for 
different purposes (not limited to ADE prediction, which is the case in our study). Some researchers, 
including Ball et al.(Ball & Botsis, 2011b) and Botsis et al.(Botsis & Ball, 2011) used network 
representations of vaccines and their reported ADEs in the FDA’s VAERS to identify the frequent patterns 
of interactions. Also Zhang et al.(Zhang, Tao, He, Kanjamala, & Liu, 2013) showed that patterns identified 
in vaccine-vaccine networks can contribute to the vaccine ontology knowledge base. A recent study by Kim 
et al.(Kim et al., 2018) on hospitalized patients with hematologic malignancies revealed that network 
centrality metrics can be used to identify the most important causes for drug-related problems (DRPs) by 
constructing a cause-DRP network using ward pharmacists’ documentations in hospital settings. 
Apart from the mentioned studies that have used descriptive and qualitative techniques to extract 
information/knowledge from networks, there are also a few studies focused on using networks of drugs and 
ADEs for predicting their associations. For instance, Atias and Sharan(Atias & Sharan, 2011) and Cami et 
al.(Cami et al., 2011) in their studies used a diffusion process and a logistic regression model, respectively, 
with NA to make ADE predictions. Nevertheless, to the best of our knowledge, NA has not been combined 
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with ML methods in the literature so far for the prediction purposes and the present study is the first one to 
do so.  
4.2.4. RESEARCH GOALS 
While statistical and machine-learning techniques have been widely used with various data sources for 
pharmacovigilance prediction purposes (Bender et al., 2007; Hammann, Gutmann, Vogt, Helma, & Drewe, 
2010; L.-C. Huang et al., 2011; LaBute et al., 2014; J. Liu et al., 2016; Pouliot et al., 2011), we found only 
a few studies that have utilized the incredible potential of network analysis approaches to explore drug-
ADE associations. Specifically, Atias and Sharan(Atias & Sharan, 2011) applied a network-based diffusion 
process to predict drugs’ ADEs. Also, in a later study, Cami et al.(Cami et al., 2011) employed logistic 
regression (LR) technique in a network approach using data from biomedical literature and chemical 
databases to predict drug-ADE associations. 
We extend the ADE prediction research by employing a Chronological Pharmacovigilance 
Network (CPN) along with machine-learning techniques to predict drugs’ ADEs. For this purpose, we use 
biomedical literature citations as the main source of data for extracting previously identified drug-ADE 
associations. Additionally, we incorporate information about the target proteins of drugs into our network 
structure to make it more informative for training machine-learning algorithms.  
A target protein is a chemically definable molecular structure that will undergo a specific 
interaction with chemicals that we call drugs because they are administered to treat or diagnose a 
disease(Imming, Sinning, & Meyer, 2006). In other words, drugs act by binding to specific target proteins 
and changing their biochemical or biophysical activities to treat their indicated diseases.(Yildirim, Goh, 
Cusick, Barabási, & Vidal, 2007) Given that, we argue that knowledge about the similarity of drugs, in 
terms of the proteins they target, can contribute to the quality of ADE predictions. Moreover, we believe 
that complexity of drug-ADE relationships is so much that machine-learning algorithms, and especially 
ensemble models are more efficient than statistical-based methods (e.g., LR) in capturing that.  
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4.3. MATERIALS AND METHODS 
4.3.1. MATERIALS 
We integrated data from two sources, namely, National Library of Medicine’s (NLM) MEDLINE and the 
DrugBank’s database of drug-target proteins, in order to operationalize our approach towards modeling of 
the CPN. MEDLINE, a subset of PubMed database, is a bibliographic database of biomedical information 
from multiple disciplines that includes more than 29M citations started from 1946. What sets MEDLINE 
apart from the rest of PubMed is the added-value of using the NLM controlled vocabulary, Medical Subject 
Headings (MeSH), for indexing, cataloging, and searching for biomedical documents. Also, DrugBank is a 
freely accessible online drug database including biological, chemical, and genetic information of 10,986 
approved and experimental drugs.    
First, we selected a sample of eight common and high-risk ADEs reported in the literature(Trifirò 
et al., 2009) (Acute renal failure, Myocardial infarction, Leukopenia, Agranulocytosis, Rhabdomyolysis,  
Neutropenia, Thrombocytopenia, and Anemia) and collected all MEDLINE articles mentioning at least one 
of them as the ADE identified in the article. To this end, we used a search strategy based on NLM’s MeSH 
thesaurus (see the appendix 2). NLM indexers select the most appropriate MeSH indexes to resume the full 
content of an article after reading the full text.(Avillach et al., 2013)  
The initially downloaded dataset involved 10,890 unique publications mentioning associations 
among 657 drugs with 769 ADEs. However, considering only drugs approved by the FDA by December 
2017, we ended up with a dataset including 9,672 publications, 582 drugs, and 732 ADEs.  
Second, we used DrugBank(Wishart et al., 2006) database to extract target proteins associated with 
each FDA-approved drug. While most drugs target only a few proteins in the human body, some have many 
targets.(Yildirim et al., 2007) In addition to the 582 drugs in initial dataset, we included information about 
217 other drugs having at least one common target with one of those 582 drugs. Therefore, the integrated 
dataset used in the study involved 799 approved drugs and 732 ADEs. The publication years as well as the 
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drugs approval dates were also imported into our data to be used in constructing training and validation 
datasets for the model building stage. All of the drugs and ADEs were then mapped to their unique terms 
from the NLM’s Unified Medical Language System (UMLS) for consistency. 
4.3.2. METHOD 
4.3.2.1. Network Construction 
A chronological approach was employed to construct drug-drug and drug-ADE relationships in the 
network. The ultimate goal in pharmacovigilance is to identify as many as possible ADEs in the pre-
marketing phase. Hence, in order to have a valid prediction model, one is only allowed to use drugs 
information as well as the known drug-ADE associations that are available prior to the time of the drug 
approval. Given this idea and using the dates of publications and drug approvals, we used all of the 
information available prior to 2001, to predict drug-ADE associations for the drugs marketed during 2001-
2017.  
First, a network was constructed in which both drugs and ADEs were considered as vertices. An 
undirected edge was created between two drugs if they had at least one common target protein. Additionally, 
a drug was connected to an ADE in the network if there was at least one PubMed article published before 
2001 mentioning such association. The network involved all of the 799 drug vertices (regardless of their 
approval dates) and 10,094 drug-drug edges indicating common target proteins, as well as 5,264 drug-ADE 
edges representing pre-2001 identified associations. We kept aside drug-ADE relationships recognized (for 
the first time) during 2001-2017 to validate our prediction model since they were unknown at the time of 





Figure 4.1. The Drug-ADE network created by Cytoscape v3.6. Triangle (blue) nodes represent drugs and circular (orange) nodes represent 
ADEs. Yellow links between drugs indicate the existence of at least one common target protein by the drugs connected. Also, gray links 
between drugs and ADEs indicate an association mentioned in at least one PubMed article for the corresponding drug and ADE. 
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4.3.2.2. Network Metrics 
Drug-ADE links were considered as the unit of analysis in this study. Since the focus of our study 
was on a set of eight common and critical ADEs, we created our dataset by considering all possible 
combinations of the 799 drugs with those ADEs (i.e., 6,392 records). Once the network was 
constructed, we extracted seven similarity- as well as three centrality-based metrics for each record 
to be used as link predictors. The metrics had been proposed in the network analysis literature for 
link prediction purposes(Cami et al., 2011; Liben-Nowell & Kleinberg, 2007; Zhou, Lü, & Zhang, 
2009).  
The three centrality-based metrics we used were the absolute difference, product, and sum 
of degree centralities of corresponding drug and ADE vertices involved in each link. All of these 
metrics were used in similar studies (Cami et al., 2011; Liben-Nowell & Kleinberg, 2007) to 
capture assortativity11 (absolute difference and ratio) and preferential attachment12 (sum and 
product). 
Table 4.1 indicates the similarity-based predictors extracted from the network along with 
their definitions. While all of the similarity metrics are defined based on the notion of commonality 
of neighborhoods between the two nodes of interest, each reflects a different aspect of similarity. 
In these definitions, Γ(i) and Di denote the set of neighbors and degree of node i, respectively. Also, 
d and a were used to denote drug and ADE, respectively. Therefore, 𝛤(𝑑) ∩ 𝛤(𝑎) refers to the set 
of common neighbors of a drug and an ADE; similarly, 𝛤(𝑑) ∪ 𝛤(𝑎) refers to the set of all of their 
neighbors.  
                                                     
11 Assortativity is defined as the extent to which highly central drugs tend to connect more frequently to 
highly- or low-central ADEs.(Cami et al., 2011) 
12 Preferential attachment denotes that the probability that a new edge has a specific node x as an endpoint, 
is proportional to the current number of neighbors of x.(Liben-Nowell & Kleinberg, 2007) 
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The network metrics were obtained with the help of the igraph package in R; a 
comprehensive package for network analysis. 
Table 4.1. Similarity Metrics and their Formulaic Definitions 
Similarity Index Definition/Formula 
Jaccard coefficient(Jaccard, 1912) |𝛤(𝑑) ∩ 𝛤(𝑎)|
|𝛤(𝑑) ∪ 𝛤(𝑎)|
 
Dice index(Dice, 1945) 2 × |𝛤(𝑑) ∩ 𝛤(𝑎)|
𝐷𝑑 + 𝐷𝑎
 





Simpson index(Simpson, 1960) |𝛤(𝑑) ∩ 𝛤(𝑎)|
𝑀𝑖𝑛(𝐷𝑑, 𝐷𝑎)
 




Apart from the five mentioned standard similarity metrics, we also incorporated two 
derived similarity metrics for each drug-ADE pair. First, for each drug-ADE pair, we calculated 
the average Jaccard similarity of the corresponding drug with all of the drugs connected to the 
ADE. To calculate this variable we constructed and used a network including only the drugs (and 
no ADEs) and extracted Jaccard similarities of each drug with all of those connected drugs. We 
believe that such a variable reflects how a new drug is chemically similar to drugs in general and 
therefore might cause the same ADE as they do. Based on the same logic and in a similar manner, 
for each drug-ADE pair in our dataset, we also incorporated average distance from the 
corresponding drug to all of the drugs connected to the ADE (i.e., the second derived variable). 
While the first derived variable captures general similarity of each drug with the connected drugs 
based on their direct neighborhoods, the second one takes into account the indirect links as well. 
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In the end, a binary target variable was created for each drug-ADE pair to indicate whether 
that association actually exists according to the MEDLINE citations. 
4.3.2.3. Training and Validation Data 
Once we formed the dataset using the network, we applied the following rules to divide the dataset 
into training and validation subsets to train the prediction models and test their efficiency.  
Drug-ADE pairs that were actually discovered after 2001, regardless of the drug approval 
year, placed into the validation dataset. All of the remaining pairs including drugs approved after 
2001 were also added to the validation set. All other pairs were classified as the training dataset. 
Applying these rules, we ended up with a training dataset containing 5,357 records with 1,087 (i.e., 
20.3%) positive responses (target=1). Also, the validation set contained 1,035 records with a 
response rate of 14.6% (i.e., 151 positives). 
4.3.2.4. Prediction Model 
We used the training dataset to train and build our prediction models. Four different classification 
algorithms were employed, namely Artificial Neural Network (ANN), Gradient Boosted Trees 
(GBT), Random Forests (RF), and Logistic Regression (LR).  
Due to the unbalanced proportion of positive and negative responses in training data, the 
Synthetic Minority Oversampling Technique (SMOTE)(Chawla, Bowyer, Hall, & Kegelmeyer, 
2002) was applied to make a balanced training (model building dataset), henceforth avoid biases in 
the training of the models. The KNIME analytics platform version 3.5.1 (a free and open source 
analytics software platform) was used to build the classification models. Figure 4.2 shows a flow-
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4.4.1. MODELS ACCURACY 
Table 4.2 shows the prediction results of the best models of each algorithm on the validation data. 
As shown, RF and GBT, the two ensemble-type of algorithms provided more accurate results than 
ANN and LR13. Also overall, GBT turned out to be the best model among all with an overall 
accuracy of 92.8% and the ability to correctly predict 72.8% of real drug-ADE associations in the 
validation data (i.e., sensitivity). It suggests that given historical information about drug-ADE 
associations as well the target proteins of drugs, our best model was able to predict 110/151 (i.e., 
72.8%) of drug-ADE associations that were actually discovered during a 17-year period after 
building the prediction network. In addition, the Positive Predictive Value (PPV) for the GBT 
model indicates that out of 143 pairs predicted as associations by this model, 110 (i.e. 76.9%) were 
real associations reported in the MEDLINE. Also overall, the PPV values highlight the superiority 
of the two ensemble models over the individual models (i.e., ANN and LR) in which only around 
half of the positive predictions were correct. 
Table 4.2. Prediction Models' Accuracy Statistics 
Model Accuracy Sensitivity PPV AUROC 
ANN 85.5% 65.6% 50.3% 0.868 
RF 92.1% 64.9% 77.2% 0.893 
GBT 92.8% 72.8% 76.9% 0.916 
LR 85.7% 56.3% 50.9% 0.793 
 
                                                     
13 The parameter settings for the best models in KNIME were as follows: 
- RF: Split criterion: Gini index; Number of models: 400; no limit on the Tree Depth and Node 
Size. 
- ANN: Number of hidden layers: 2; Number of neurons per layer: 5; Maximum number of 
iterations: 60. 
- GBT: Number of model: 300; Learning rate: 0.3; Tree depth limit: 4; No attribute sampling.  
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In the only similar study we are aware of in the literature, conducted by Cami et al.,(Cami 
et al., 2011) historical drug-ADE associations along with drugs’ taxonomical and intrinsic 
properties (e.g., molecular weight, atom count, and so on) from pre-2005 years were used in 
multiple LR models to predict associations identified during 2005-2010. Comparing to their best 
model (AUROC=0.869), two of our prediction models (RF and GBT) provide superior results 
while prediction power of our ANN model is also comparable to theirs.  
Our further investigation revealed that from the 110 true positive predictions made by the 
GBT model, 29 were related to post-2001 marketed drugs, which, given 42 actual positive 
associations, means a 69% true positive rate for these new drugs. The true positive rate for older 
drugs was 74.3% (i.e., 81/109 actual associations). Moreover, it turned out that out of 143 positive 
predictions, 102 were related to pre-2001 marketed drugs, which (given that 81 of the true positive 
cases were pre-2001 marketed drugs) suggests a PPV of 79.4% (81/102) for this group. Also, 41 
positive predictions were related to post-2001 marketed drugs resulted in a PPV of 70.7% (i.e. 
29/41). These statistics seem reasonable given the higher number of historical publications about 
these drugs that makes the model better trained for classifying their associations.  
Furthermore, in terms of sensitivity, our approach outperforms Cami et al.’s, where their 
best-reported model had a sensitivity of 61.2% compared to 72.8% of our model. While this 
difference might be argued to be due to the narrower focus of our study (i.e., including 8 ADEs), 
we believe it mostly has to do with the more informative nature of the network we used to train our 
models as well as the ability of machine-learning techniques to capture complex/non-linear 
relationships compared to statistical methods like LR. As Table 4.2 shows, our LR model did not 
perform as good as the other three machine-learning methods. Nevertheless, it is still comparable 
and complementary to the models provided by Cami et al.(Cami et al., 2011) Even comparing our 
results to those of the studies that have employed machine-learning techniques (mostly using drugs’ 
structural variables as predictors) with a non-network approach(L.-C. Huang et al., 2011; L. Huang 
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et al., 2013; M. Liu et al., 2012), our approach outperforms theirs in terms of most of the accuracy 
statistics. Table 4.3 indicates that especially in terms of sensitivity and PPV, using an ensemble 
machine-learning model along with the network approach has significantly improved ADE 
predictions. 
Table 4.3. Comparison of model results with the best results reported by similar studies 
Article Network 
approach 
Model Chem. Bio. Other Acc Sens PPV AUROC 
Liu et al. (M. 
Liu et al., 2012) 
No SVM Yes Yes Yes 0.967 0.631 0.662 0.952 
Huang et al.(L. 
Huang et al., 
2013) 
No SVM Yes Yes No NR NR NR 0.760 
Cami et 
al.(Cami et al., 
2011) 
Yes LR Yes No Yes NR 0.608 NR 0.869 
Huang et al.(L.-
C. Huang et al., 
2011) 
No SVM No Yes No 0.675 0.632 NR 0.771 
Present study Yes GBT No Yes No 0.928 0.728 0.769 0.916 
*Chem. indicates whether chemical features of drugs are used for ADE prediction.*Bio. Indicates whether 
biological features of drugs are used for ADE prediction.*Other indicates whether other features (e.g. 
taxonomical, phenotypical, etc.) of drugs are used for ADE prediction. 
 
4.4.2. VARIABLES IMPORTANCE 
Having the superior prediction model identified, we further investigated how each of the predictors 
contributed to the model accuracy. To this end, we dropped predictor variables one at a time from 
our data and ran the best prediction model. Each time we recorded model’s AUROC to be compared 
to that of the original model. Table 4.4 indicates the amount of decrease in AUROC after dropping 





Table 4.4.  Variable Importance Statistics 
Dropped Variable New AUROC AUROC_diff 
Relative 
Importance 
Degree_product 0.86 0.056 1 
Degree_ratio 0.864 0.052 0.875 
Degree_sum 0.872 0.045 0.656 
Geometric index 0.884 0.032 0.250 
Avg_Jacc_connected 0.885 0.031 0.219 
Adamic/Adar index 0.887 0.029 0.156 
Simpson index 0.887 0.029 0.156 
Dice index 0.888 0.028 0.125 
Jaccard index 0.889 0.027 0.094 
Avg_dist_connected 0.891 0.025 0.031 
Abs_degree_diff 0.892 0.024 0 
 
As shown in this table Degree_product, Degree_ratio, and Degree_sum representing 
preferential attachment as well as assortativity of drug-ADE pairs turned out to have the highest 
contribution to the predictive power of the best (i.e., GBT) model. It suggests that our centrality-
based predictors generally played a more important role than similarity-based metrics. Of the three 
top predictors, two of them (Degree_product and Degree_sum) were also among the top three in 
the study performed by Cami et al..(Cami et al., 2011) Degree_product was also identified as a 
strong predictor in the work conducted by Liben-Nowell & Kleinberg.(Liben-Nowell & Kleinberg, 
2007) Interestingly, the results show that one of the derived variables, namely 
Avg_Jacc_connected, was the fifth most important predictor with a relative importance of around 
22%. Also consistent with prior research,(Cami et al., 2011) Abs_degree_diff was the least 
important predictor of network links. 
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Finally, by investigating our true positive predictions and considering the actual years that 
corresponding drug-ADE associations were identified for the first time, we realized that, on 
average, our model was able to predict ADEs 3.84 years (SD=1.97 years) before they were 
mentioned in PubMed articles.  Table 4.5 indicates a summary of associations predicted by the 
model for the eight ADEs of interest along with the top associated drug predicted for each. The 
“average probability” column in this table shows the average across all the real associations, not 
just those that correctly predicted. The results show that disregarding a few exceptions, the model 
performance in predicting associations across the ADEs of interest was roughly the same. This 
suggests generalizability of the proposed approach as it has performed equally well with regard to 
various ADEs. 












Acute Renal Failure 32 26 (81%) 3.62 0.7655 Ceftazidime (2)* 
Agranulocytosis 12 10 (83%) 5.70 0.8293 Albendazole (6) 
Anemia 9 6 (67%) 2.67 0.7277 Ribavirin (3) 
Leukopenia 4 4 (100%) 3 0.9436 Dexamethasone (1) 
Myocardial Infarction 27 18 (67%) 3.72 0.7035 Doxazosin (5) 
Neutropenia 17 12 (71%) 3.83 0.7739 Flucytosine (2) 
Rhabdomyolysis 40 27 (68%) 3.92 0.6910 Doxylamine (0) 
Thrombocytopenia 10 7 (70%) 3.50 0.7517 Tamoxifen (0) 
*The numbers in front of drug names in the last column indicate the number of years the model predicted 




4.4.3. ANALYSIS OF PREDICTION ERRORS 
Even though our prediction model performed well in terms of common accuracy metrics, it is 
always insightful to qualitatively analyze the cases that a model fails to accurately predict. Such an 
undertaking may involve both the drug-ADE pairs that were predicted to be associated while they 
actually were not (i.e., the false positive cases) and the drug-ADE pairs that were actually associated 
whereas the model failed to predict their association correctly (i.e., the false negative cases). 
We found 41 false negative predictions made by the model. Our further investigation 
revealed that 20 (i.e., around half) of them are related to the drugs approved after 2008. More 
specifically, we realized that six drugs, all approved after 2008, account for 17 (i.e., 41%) of false 
negative predictions. We then looked into the known associated ADEs, other than the eight ADEs 
of interest, for each of those six drugs before 2001 (i.e., when they were experimental drugs yet) 
which were used to train the prediction model. We found out that, compared to average (i.e., 6.58), 
the number of known associations for most of those six drugs was considerably low with only one 
having more than 5 known ADEs. Given these findings, we believe that one main reason for the 
model making those false negative predictions could be the relatively low number of known ADE 
associations (i.e., network edges) involving those drugs in the training dataset. Since we only used 
network metrics as the predictor variables, such lack of sufficient drug-ADE edges may possibly 
affect all of the predictor variables related to the corresponding drugs. Of course, one way to address 
this issue is to change the cutoff point for data partitioning (which is currently 2001) so that our 
training data include more of the known MEDLINE citations involving the drugs approved more 
recently. In the present study, however, changes in the cutoff year considerably affect the size of 
validation dataset14, which could jeopardize the validity of the prediction model. 
                                                     
14. For instance, we changed the cutoff year to 2003 and we ended up with only 732 records (i.e. a decrease 
of 303 records) in the validation dataset. 
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Our predictions also involved 33 false positive cases. Again, to further investigate the 
potential causes for those classification errors we looked into the specific drugs and ADEs involved. 
We realized that around 61% (i.e., 20) of these cases were related to the relatively older drugs, 
approved in early 90’s or even earlier. For such drugs, due to numerous biomedical studies 
conducted on them over time, the number of known ADE associations and consequently their 
degree centrality in the network tend to be higher than newer drugs. This directly inflates the 
centrality-based predictors of drug-ADE pairs, namely degree_ratio, degree_sum, and 
degree_product. Moreover, it was shown that these were the top three influential predictors of 
network links in our study. Table 4.6 compares the values of these three predictors, on average, for 
the false positive versus true positive as well as true negative cases. Clearly, the predictor values in 
false positive cases are far from those of the true negative cases and are very close to the cases 
correctly predicted as positive. 
Table 4.6. Comparing Top Predictors’ Values in False Positive, True Positive, and False 
Negative Predictions 
Predictor False Positives True Positives True Negatives 
Degree_Sum 234.82 237.55 203.05 
Degree_Product 7131.76 7615.02 3344.65 
Degree_Ratio 0.21 0.23 0.11 
 
Overall, our findings suggest that for older drugs the centrality-based predictor values are 
overly inflated, due to the higher number of citations involving in them, that other predictor 
variables cannot help the model to discern those cases from actual/real positive cases. Hence, 
probably incorporating some other network-independent informative covariates suggested in the 
literature (e.g., molecular or chemical features of drugs) can address this issue to some extent and 
help the model to better differentiate between positive and negative cases. 
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4.5. DISCUSSION AND CONCLUSION 
In this study, we proposed a new approach to predict ADEs by constructing drug-ADE networks, 
using biomedical citations as well as drugs target proteins information, and then employing network 
metrics as predictors of associations in machine-learning algorithms. 
While both NA approaches and ML techniques had been employed in the past separately, 
to the best of our knowledge, the present study is the first one, which employs ML along with an 
NA approach together in a single study. The promising results we obtained suggest that combining 
these two powerful tools can enhance the results we may get from each in separation. Our proposed 
approach outperformed the prior studies (see Table 4.) while the number of predictor variables used 
in this study is relatively lower than that of the similar studies. 
We believe that part of these superior results owes to the incredible power of ensemble 
machine-learning algorithms. As shown in our results, the two ensemble algorithms (i.e., RF and 
GBT) considerably outperformed the other two approaches. That is simply because of the higher 
power of ensemble algorithms in capturing sophisticated patterns in the data. While statistical and 
regular machine-learning techniques train a single model (either linear or non-linear) to reflect the 
relationship between the variables, ensemble algorithms sample the data hundreds of times and use 
those samples to build hundreds of prediction models. Then to predict a new case they vote from 
the created models to specify the final prediction. This way, instead of a single model, which is 
subject to sample randomization errors, many models are employed to yield predictions. 
The results also suggest that assortativity and preferential attachment (i.e., centrality-based 
metrics) are better predictors of network edges than similarity-based metrics (e.g., Jaccard 
coefficient). This is in line with the results from Cami et al.(Cami et al., 2011) and Liben-Nowell 
& Kleinberg(Liben-Nowell & Kleinberg, 2007). Additionally, we introduced two derived 
similarity-based network metrics, namely Avg_Jacc_connected and Avg_Distance_connected, for 
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predicting network edges, and it turned out that the former is among the top five most important 
predictors. In terms of relative importance, Table 4. shows that this derived variable has contributed 
to the quality of model around 50% more than the Adamic/Adar index and around 100% more than 
Jaccard index, two popular similarity-based metrics. It suggests that considering the similarity of a 
drug with the drugs already associated with an ADE provides more useful information in predicting 
drug-ADE associations, than considering the similarity of that drug with the ADE itself. 
Although the present study is particularly focused on eight highly common and risky 
ADEs, we argue that the high accuracy of our predictions has nothing to do with that matter because 
we did not incorporate any information about the ADEs or their relationships in building our 
prediction models. All of the information used to train our prediction models were historical drug-
ADE associations as well as drug-target proteins. Hence, we believe that replicating our approach 
on a larger scale and with a higher number of ADEs would result in the same quality results, if not 
better. 
Another limitation of this study is that it does not account for the strength of drug-ADE 
associations in the construction of the network. In network analysis, using the strengths of 
associations as the linkage weights and extracting weighted metrics is a popular and informative 
approach provided that the weights are assigned to the links in a meaningful way. Considering the 
frequency of citations mentioning a given association as the strength of that association is not a 
decent and even meaningful way for weighing the network edges because this frequency does not 
necessarily reflect the strength of association and might very well be, for instance, due to the high 
amount of risk involved in the corresponding ADE. Therefore, in this study, we used an unweighted 
network for the analysis. Future research could extend our approach by developing a way to score 
drug-ADE associations and use weighted network metrics in building the prediction models.  
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While our best model performed well in terms of sensitivity, it still made 33 false positive 
and 41 false negative predictions. Even though we analyzed some potential reasons for these 
prediction errors, we suspect that a portion of the false positive cases, especially those involved 
recently approved drugs, might be actually real drug-ADE associations that have not yet been 
studied and mentioned in biomedical citations. This could be also the case with all the other ADE 
prediction studies where the models yield a considerable number of false positives. Future research 
may focus on such cases resulted from ADE predictions and try to investigate them using clinical 
trials or by analyzing patients transactions from EHR data using methods like prescription sequence 
symmetry analysis(Pratt et al., 2015; Tsiropoulos, Andersen, & Hallas, 2009). 
Given the relatively high accuracy of predictions resulted from employing network 
approach, both in this study and the other few similar works, we strongly encourage future 
researchers to utilize the incredible power of networks for prediction purposes in 
pharmacovigilance. Especially, we believe that incorporating more data sources to construct more 
informative training networks can lead to even better predictions in the future. Specifically, 
chemical, physical, and molecular features of drugs (e.g., molecular weight, heavy atom count, 
melting point, etc.) can be added to the model as covariates to enhance its prediction power. We 
believe that one big methodological advantage of our study is producing quality results using a 
considerably lower number of predictors than prior studies (Atias & Sharan, 2011; Cami et al., 
2011; L.-C. Huang et al., 2011; M. Liu et al., 2012) and relying mostly on the power of networks 
and ensemble ML algorithms to identify patterns. Nevertheless, as discussed in the Results section, 
incorporating some additional covariates can potentially improve the model while maintaining its 
simplicity. Databases such as DrugBank and PubChem are freely accessible and rich sources of 
information about drugs that can be used for this purpose. 
We used the biomedical literature citations as the only resource for the known drug-ADE 
associations in constructing the network. There are, however, some other resources such as the side 
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effect resource (SIDER) database (http://www.sideeffects.embl.de) or some commercial databases 
like Lexicomp (http://www.lexi.com) that can be used for this purpose as well. Future research may 
extend our approach by incorporating multiple resources to add as many as possible drug-ADE 
links to the network since doing so can enhance the information extend of the network and 
potentially improves the quality and accuracy of the predictions. 
Similarly, with regard to the drug targets, we only used a single source (i.e. DrugBank) for 
this purpose. Even though it was suggested in prior research(Barneh, Jafari, & Mirzaie, 2015) that 
network-based organization of DrugBank data, particularly the drug similarity network (DSN), can 
potentially contribute to the prediction of side effects, and we showed that in this study, yet it 
involves some potential limitations. DrugBank is primarily focused on labeling targets from a 
pharmacokinetic point of view and possibly includes some determinants of drug disposition labeled 
as drug targets. We are not sure, though, whether the existence of such instances has improved or 
limited our model performance since on one hand, they may make the DSN more information-rich, 
but on the other hand, the nature of drug similarities may not be the same across the network.  
Finally, we believe that the chronological settings used in the present study to construct a 
drug-ADE network based on the chronological drug approvals and known ADE associations may 
be extended by future researchers to conduct a longitudinal study by constructing multiple drug-
ADE networks at different time points and show that evolution of this network over time enriches 







SUMMARY AND CONCLUSION 
 
 
With advances in computer science and data science in the past few decades and given the huge 
amount of data being accumulated every day on the health care data repositories, computer-based 
data analytics approaches have been widely developed and applied with the aim of improving 
health care processes.  
One of the areas of health care which has been benefited from such efforts is drug safety. 
Traditionally, a newly discovered drug had to pass through decades of randomized clinical trials 
before being approved by the health care authorities and provided to the market. That was 
basically due to great deal of uncertainty with regard to the various types of risks posed by 
administering the drug to the real patients. Data analytics and statistical methods have 
significantly contributed to drug safety by reducing such risks of uncertainty through analyzing 
data from historical medication usage as well as chemical structures and biomedical 
characteristics of drugs. These efforts has led to more timely detection, more accurate prediction, 




In the first essay, an analytics approach has been extended with the aim of taking into account 
drug-drug interactions in determining the confounding role of particular medications with regard 
to developing an adverse event. While each medication, in isolation, may lead to various adverse 
events in a patient, in a real world patients are usually being prescribed with multiple medications 
either for a single condition or for multiple conditions diagnosed. So the question is how taking 
other drugs may intensify or mitigate the already identified effect of a given drug in developing 
its corresponding adverse events? In other words, how can we realize the confounding role of a 
given drug with regard to a known and established drug-ADE relationship. By extending an 
emergent pattern mining method and applying it to the real prescription records of more than 
370,000 diabetic patients, in the first study we examined such confounding roles for a group of 
common diabetic medications on the adverse effect of a group of drugs known to cause acute 
kidney failure. The results explain the contradictory roles reported in the medical literature for the 
confounding role of common diabetic medications in absence of other potentially relevant 
medications. 
The second essay provides two independent approaches to examine the effect of prescription 
sequence on the likelihood of developing adverse drug events. While the sequence by which a 
given set of drugs are administered was suggested in the literature as a potential factor in 
developing adverse events, this effect was not empirically examined in the past. The two designed 
data analytic approaches were applied to the prescription records of a large group of diabetic 
patients to examine the effect of sequence on developing acute renal failure, as a common adverse 
event among this type of patients. The results obtained from the two independent approaches 
consistently revealed a significant effect on the likelihood of developing renal failure, which was 
attributable to the drugs’ prescription sequence. 
90 
 
In the third essay, two freely accessible feature-rich data sources, namely MEDLINE and 
DrugBank, were employed to construct a network of drugs and their associate adverse events 
already mentioned in the biomedical literature. The idea in this study was to use the known drug-
ADE associations as well as similarities between the newly discovered drugs with already-
marketed drugs in terms of their target proteins in the human body to predict potential ADEs of 
the new drugs. Our results showed that employing network metrics as the predictors of drugs’ 
ADE along with using advanced ensemble machine learning algorithms can significantly improve 
the accuracy of ADE predictions. 
5.2. ASSUMPTIONS AND LIMITATIONS 
The present work involves several limitations as discussed below. 
In the first and second study, even though we limited our sample to diabetic patients and 
controlled for their demographics, diabetes history, and common diabetic medications, still some 
important factors were not controlled due to sample limitations. Of the highest importance was 
the effect of patients' exact comorbidities that we did not control for in these two study because 
doing such would greatly affect our sample size. It was not easy to find a control match for each 
case patient with exactly the same comorbidities. Hence, we limited this control to only a major 
disease which is highly prevalent among Americans (i.e., diabetes) and also controlled for the 
total number of comorbidities as a general measure of patients’ wellness. We also implicitly 
assumed that by controlling for age and other demographics we are also partly controlling for 
other particular comorbidities that might be attributable to aging. 
In the same studies we assumed that all the medications prescribed by doctors were administered 
by the patients until it was discontinued by their doctor again. In fact, it was not practically 
possible to monitor whether every drug had been administered as recommended. However, we 
believe that it is reasonably realistic to assume that medications prescribed in a particular visit 
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were taken before those prescribed in the subsequent visit. Accordingly, instead of taking into 
account prescription timestamps we considered the timestamps of doctor visits as the base for 
sequence analysis in the second essay.  
Moreover, a limitation in the third study is that it does not account for the strength of drug-ADE 
associations in the construction of the network. In network analysis, using the strengths of 
associations as the linkage weights and extracting weighted metrics is a popular and informative 
approach provided that the weights are assigned to the links in a meaningful way. Then future 
research could extend our approach by developing a way to score drug-ADE associations and use 
weighted network metrics in building the prediction models. Additionally, with regard to the drug 
targets, we only used a single source (i.e. DrugBank) for this purpose. Even though it was suggested 
in prior research (Barneh et al., 2015) that network-based organization of DrugBank data, 
particularly the drug similarity network (DSN), can potentially contribute to the prediction of side 
effects, and we showed that in the third study, yet it involves some potential limitations. DrugBank 
is primarily focused on labeling targets from a pharmacokinetic point of view and possibly includes 
some determinants of drug disposition labeled as drug targets. We are not sure, though, whether 
the existence of such instances has improved or limited our model performance since on one hand, 
they may make the DSN more information-rich, but on the other hand, the nature of drug 
similarities may not be the same across the network.  
5.3. FUTURE RESEARCH DIRECTIONS 
This work leads to several areas of future research in drug safety as discussed next. 
a) Studying the confounders of high-risk adverse events: as discussed in the first study, 
acute renal failure was studied as the case in that work because it was identified as a 
high-risk ADR in the medical literature, that can lead to death in case of occurrence. 
There are, however, several other high-risk ADRs (e.g., myocardial infarction) common 
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among different groups of patients that need to be studied in terms of their associated 
drugs and the confounding role of other relevant drugs in decreasing or increasing the 
likelihood of developing them. Also future research may expand the proposed approach 
in the first study by employing larger data set (involving a wider time window) which 
allows for controlling the effect of specific diseases (as opposed to controlling only for 
the total comorbidities) as well. 
b) Designing an automated decision support system to monitor prescription sequences: as 
discussed in the second study, the sequence by which medications are administered can 
play a significant role in developing ADRs. Future research may employ large sets of 
historical prescription records to identify the sequential patterns leading to each given 
ADR and then use those identified patterns to design a clinical decision support system. 
Such a system can monitor the prescription records of each particular patient and provide  
the physicians with appropriate alerts when there is some intensified risk of developing a 
high-risk ADR involved, due to prescribing drugs in certain sequences. 
c) Using network analytics and ensemble machine learning to improve ADR predictions: in 
the  third study it was shown that how employing network metrics along with ensemble 
machine learning algorithms can help in identifying  sophisticated patterns within drug-
ADR associations and apply them effectively in predicting potential ADRs for newly 
discovered drugs. Future research may extend this idea by constructing more feature-rich 
networks of drugs and ADRs and extracting and developing new network metrics to be 
used as predictors of ADRs. In addition, with recent advances in computer hardware and 
provision of infrastructures for conducting deep learning analyses, future research may 
employ data sets including a large number of chemical, biomedical, and physical features 
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The list of kidney-damaging (KD) as well as common diabetic medications included in the study 
follows. 
GENERIC_NAME Type GENERIC_NAME Type GENERIC_NAME Type 
acetaminophen KD bevacizumab KD insulin (variations) Diabetic 
aspirin KD indomethacin KD metformin Diabetic 
pantoprazole KD hydroxychloroquine KD glipizide Diabetic 
vancomycin KD pamidronate KD sitagliptin Diabetic 
ketorolac KD doxycycline KD glyburide Diabetic 
esomeprazole KD azithromycin KD glimepiride Diabetic 
tacrolimus KD clindamycin KD pioglitazone Diabetic 
ciprofloxacin KD tenofovir KD linagliptin Diabetic 
ibuprofen KD ketoprofen KD repaglinide Diabetic 
sulfamethoxazole-
trimethoprim 
KD mitomycin KD saxagliptin Diabetic 
omeprazole KD sulindac KD acarbose Diabetic 
lansoprazole KD captopril KD liraglutide Diabetic 
cyclosporine KD   nateglinide Diabetic 
phenytoin KD   canagliflozin Diabetic 
cephalexin KD   exenatide Diabetic 
acyclovir KD   bromocriptine Diabetic 
naproxen KD   saxagliptin Diabetic 
diclofenac KD   acarbose Diabetic 






This appendix describes the search strategy used for extracting data from the National Library of 
Medicine’s (NLM) MEDLINE database of biomedical citations. MEDLINE is a subset of PubMed 
database and includes more than 26 million biomedical citations started from 1946 onward. Each 
article is carefully read and annotated by a group of trained indexers using a vocabulary system 
called Medical Subject Headings (MeSH). The MeSH thesaurus is a controlled vocabulary system 
produced by NLM to be used for indexing, cataloging, and searching for biomedical citations and 
health-related documents. After carefully reading an article, the NLM indexing experts select the 
most appropriate descriptors and subheadings (a.k.a. qualifiers) that best describe the content.  
To extract required data for the present study we downloaded all the MEDLINE citations from 
PubMed (https://www.ncbi.nlm.nih.gov/pubmed) with the “AE” MeSH subheading, which is used 
to indicate mentions of Adverse Effects, and containing at least one of the 8 high-risk ADEs of 
interest indexed as “Chemically induced”. These two MeSH indexes, together, specify the drug and 
the adverse event mentioned as an association in a given article. For instance, the combination of 
"acetaminophen/AE" and "Acute kidney failure/chemically induced" for a given article indicates 
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that a drug-ADE association suggesting the potential adverse effect of acetaminophen on 
developing kidney failure is mentioned in that study. 
The search was done multiple times, each time for one of the ADEs of interest; however, at the 
end, we removed duplicated citations from our records. For each article, the following information 
was collected: article PubMed ID (PMID), MeSH descriptors, subheadings, substances, and date 
of publication.  
Since drugs’ target protein and date of approval information were to be extracted from another 
resource (i.e., DrugBank), we then used the Unified Medical Language System (UMLS) to map the 
drug and ADE terms. UMLS is a biomedical terminology integration system handling more than 
150 terminologies including MeSH. It integrates various alternatives of the same biomedical 
concepts and assigns each concept a unique identifier (CUI) across the whole database. All the drug 
and ADE terms in the collected dataset were mapped to their corresponding UMLS terms and the 
CUI associated with each was queried and added to the dataset.  
The list of approved FDA drugs along with their target proteins was downloaded from DrugBank’s 
(https://www.drugbank.ca ) Therapeutic Target Database (TTD) ver. 6.1.01 and mapped to UMLS 
terms as well. Then the list was used to filter the articles collected from MEDLINE so that we only 
kept articles including approved drugs and put away studies focusing on experimental drugs or 
chemical compounds. 
Finally, drug-ADE pairs were created by matching mentions of the “AE” and “Chemically 
induced” tags in the same publications and the corresponding publication dates were assigned to 
the created pairs. Repeated pairs were then identified and redundancies were removed by 
maintaining only the earliest drug-ADE mention (based on dates). Also using the DrugBank data, 
drug-drug pairs were created by matching the drugs sharing at least one target protein. 
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The created pairs were then used as the input to both Cytoscape v3.6.0 and the igraph package in 







Candidate for the Degree of 
Doctor of Philosophy 
Dissertation: USING BIG DATA ANALYTICS AND STATISTICAL METHODS FOR 
IMPROVING DRUG SAFETY 
Major Field: Business Administration (MSIS) 
Biographical: 
Educational: 
Completed the requirements for the Doctor of Philosophy in Business Administration 
(MSIS) at Oklahoma State University, Stillwater, Oklahoma in May 2019 
Completed the requirements for the Master of Science in Industrial Engineering at 
University of Tehran, Tehran, Iran in 2012 
Completed the requirements for the Bachelor of Science in Industrial Engineering at 
Isfahan University of Technology, Isfahan, Iran in 2009 
Experience: 
Graduate Teaching Associate at the MSIS Department, Oklahoma State University, 
Stillwater, Oklahoma, 2014-2019. 
 
Professional Memberships: 
Association for Information Systems (AIS), 2016-2019. 
Decision Sciences Institute (DSI), 2016-2019. 
Institute of Operations Research and Management Sciences (INFORMS), 2016-2019. 
